

CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2022



**NATIONAL CANCER
CONTROL PROGRAMME**
MINISTRY OF HEALTH



National Cancer Incidence and Mortality Data Sri Lanka 2022



**National Cancer Control Programme
555, Public Health Complex
Elvitigala Mawatha
Narahenpita, Colombo 5**

24th Publication – National Cancer Incidence and Mortality Data Sri Lanka: 2022

Published in November 2025

ISBN No. 978-624-6511-50-0

Compiled by

Strategic Information Management (SIM) Unit
National Cancer Control Programme
Ministry of Health and Mass Media

Published by



Contact: No +94 112368627, Fax +94 112368627

Email: nccpsl@yahoo.com

Web: www.nccp.health.gov.lk



National Cancer Control Programme, Sri Lanka

Printed by

Tharanjee Prints (Pvt) Ltd
506, Highlevel Road, Nawinna, Maharagama
0112 804 773, 0112 801 308

Table of Contents

List of Tables	iv
List of Figures	vi
Message from the Director General of Health Services	ix
Message from the Deputy Director General of Non- Communicable Disease	xi
Foreword from the Director, National Cancer Control Programme	xiii
List of Contributors	xv
List of Acknowledgement	xvi
Executive Summary	1
Introduction	5
Methodology	6
Cancer Incidence Data of Sri Lanka - 2022	13
Cancer Mortality Data of Sri Lanka	106
Statistical terminology	117
List of References	119

List of Tables

Table No	Description	Page No
Table 1:	Distribution of government cancer treatment centres in year 2022	07
Table 2:	Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2022	08
Table 3:	Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2022	09
Table 4:	Estimated mid-year population by five-year age groups in Sri Lanka, 2022	11
Table 5:	Estimated mid-year population by the district in Sri Lanka, 2022	12
Table 6:	Cancer Incidence by sex in Sri Lanka, 2005-2022	14
Table 7:	Cancer Incidence by 5-year age groups and sex in Sri Lanka, 2022	16
Table 8:	Leading cancer site by sex in Sri Lanka, 2022	17
Table 9:	Number of cancers by 5-year age groups and ICD 10 site, among males in Sri Lanka, 2022	25
Table 10:	Number of cancers by 5-year age groups and ICD 10 site, among females in Sri Lanka, 2022	27
Table 11:	Number of cancers by 5-year age group and ICD 10 site categories among males in Sri Lanka, 2022	29
Table 12:	Number of Cancers by 5-year age group and ICD 10 site categories among females in Sri Lanka, 2022	30
Table 13:	Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by 5-year age group and ICD 10 site categories among males in Sri Lanka, 2022	31
Table 14:	Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by 5-Year age group and ICD 10 site categories among females in Sri Lanka, 2022	32
Table 15:	Lip, Tongue and Mouth cancer incidence data in Sri Lanka, 2022	33
Table 16:	Pharyngeal cancer incidence data in Sri Lanka, 2022	36
Table 17:	Oesophageal cancer incidence data in Sri Lanka, 2022	39
Table 18:	Stomach cancer incidence data in Sri Lanka, 2022	41
Table 19:	Colon and rectum cancer incidence data in Sri Lanka, 2022	43
Table 20:	Laryngeal cancer incidence data in Sri Lanka, 2022	46
Table 21:	Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2022	48
Table 22:	Skin cancer incidence data in Sri Lanka, 2022	51
Table 23:	Breast cancer incidence data in Sri Lanka, 2022	54
Table 24:	Cervix uteri cancer incidence data in Sri Lanka, 2022	57
Table 25:	Uterine cancer incidence data in Sri Lanka, 2022	59
Table 26:	Ovary cancer incidence in Sri Lanka, 2022	62
Table 27:	Prostate cancer incidence data in Sri Lanka, 2022	65
Table 28:	Urinary bladder cancer incidence data in Sri Lanka, 2022	67

Table 29: Thyroid gland cancer incidence data in Sri Lanka, 2022	69
Table 30: Lymphoma incidence data in Sri Lanka, 2022	71
Table 31: Leukaemia incidence data in Sri Lanka, 2022	74
Table 32: Basis of diagnosis of cancer patients in Sri Lanka, 2022	78
Table 33: Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2022	80
Table 34: Overall cancer incidence by province and district in Sri Lanka, 2022	85
Table 35: Leading cancer incidence data by sex and district in Sri Lanka, 2022	86
Table 36: Deaths due to neoplasm out of all deaths reported to Vital Registration System of Sri Lanka, 2001-2022	106
Table 37: Deaths due to neoplasm by sex out of all deaths reported to Vital Registration System of Sri Lanka, 2001-2022	107
Table 38: Number of deaths and Crude Death Rates due to cancer by sex and site of cancer based on deaths reported to Vital Registration System of Sri Lanka, 2020	109
Table 39: Deaths due to cancer among males and females in hospitals in Sri Lanka, 2005-2022	114
Table 40: Deaths due to cancer in hospitals, crude hospital annual death rates due to cancer and proportionate mortality ratio for cancer out of all hospital deaths in Sri Lanka, 2005-2022	115
Table 41: Hospitalizations, hospital deaths and case fatality rate due to cancer in year 2022 by RDHS divisions in Sri Lanka	116

List of Figures

Figure No	Description	Page No
Figure 1:	Flow diagram of the process of cancer registration in Sri Lanka	6
Figure 2:	Population pyramid of Sri Lanka in 2022 by 5-year age groups	13
Figure 3:	Crude Cancer Incidence Rates of Sri Lanka, 2005-2022	15
Figure 4:	Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2022	15
Figure 5:	Cancer Incidence Rates of Sri Lanka in 2022	16
Figure 6:	Age Specific Cancer Incidence Rates of Sri Lanka, 2022	17
Figure 7:	Proportion of leading cancers in males in Sri Lanka, 2022	18
Figure 8:	Proportion of leading cancers in females in Sri Lanka, 2022	18
Figure 9:	Crude incidence rates of leading cancers in males in Sri Lanka, 2022	19
Figure 10:	Crude incidence rates of leading cancers in females in Sri Lanka, 2022	19
Figure 11:	Leading cancers by 00-14 year age group among males in Sri Lanka, 2022	20
Figure 12:	Leading cancers by 00-14 year age group among females in Sri Lanka, 2022	20
Figure 13:	Leading cancers by 15-34 year age group among males in Sri Lanka, 2022	21
Figure 14:	Leading cancers by 15-34 year age group among females in Sri Lanka, 2022	21
Figure 15:	Leading cancers by 35-49 year age group among males in Sri Lanka, 2022	22
Figure 16:	Leading cancers by 35-49 year age group among females in Sri Lanka, 2022	22
Figure 17:	Leading cancers by 50-64 year age group among males in Sri Lanka, 2022	23
Figure 18:	Leading cancers by 50-64 year age group among females in Sri Lanka, 2022	23
Figure 19:	Leading cancers by 65 year and above age group among males in Sri Lanka, 2022	24
Figure 20:	Leading cancers by 65 year and above age group among females in Sri Lanka, 2022	24
Figure 21:	Age Specific Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2022	35
Figure 22:	Age Standardized Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2005-2022	35
Figure 23:	Age Specific Incidence Rates of Pharyngeal cancer in Sri Lanka, 2022	38
Figure 24:	Age Standardized Incidence Rates of Pharyngeal cancer in Sri Lanka, 2012-2022	38
Figure 25:	Age Specific Incidence Rates of Oesophageal cancer in Sri Lanka, 2022	40
Figure 26:	Age Standardized Incidence Rates of Oesophageal cancer in Sri Lanka, 2005-2022	40
Figure 27:	Age Specific Incidence Rates of Stomach cancer in Sri Lanka, 2022	42
Figure 28:	Age Standardized Incidence Rates of Stomach cancer in Sri Lanka, 2005-2022	42
Figure 29:	Age Specific Incidence Rates of Colon and rectum cancer in Sri Lanka, 2022	45
Figure 30:	Age Standardized Incidence Rates of Colon and rectum cancer in Sri Lanka, 2005-2022	45
Figure 31:	Age Specific Incidence Rates of Laryngeal cancer in Sri Lanka, 2022	47
Figure 32:	Age Standardized Incidence Rates of Laryngeal cancer in Sri Lanka, 2005-2022	47
Figure 33:	Age Specific Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2022	50
Figure 34:	Age Standardized Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2005-2022	50
Figure 35:	Age Specific Incidence Rates of Skin cancer in Sri Lanka, 2022	53
Figure 36:	Age Standardized Incidence Rates of Skin cancer in Sri Lanka, 2005-2022	53

Figure 37: Age Specific Incidence Rates of Breast cancer in Sri Lanka, 2022	56
Figure 38: Age Standardized Incidence Rates of Breast cancer in Sri Lanka, 2005-2022	56
Figure 39: Age Specific Incidence Rates of Cervical cancer in Sri Lanka, 2022	58
Figure 40: Age Standardized Incidence Rates of Cervical cancer in Sri Lanka, 2005-2022	58
Figure 41: Age Specific Incidence Rates of Uterine cancer in Sri Lanka, 2022	61
Figure 42: Age Standardized Incidence Rates of Uterine cancer in Sri Lanka, 2006-2022	61
Figure 43: Age Specific Incidence Rates of Ovarian cancer in Sri Lanka, 2022	64
Figure 44: Age Standardized Incidence Rates of Ovarian cancer in Sri Lanka, 2005-2022	64
Figure 45: Age Specific Incidence Rates of Prostate cancer in Sri Lanka, 2022	66
Figure 46: Age Standardized Incidence Rates of Prostate cancer, 2005-2022	66
Figure 47: Age Specific Incidence Rates of Urinary bladder cancer in Sri Lanka, 2022	68
Figure 48: Age Standardized Incidence Rates of Urinary bladder cancer in Sri Lanka, 2005-2022	68
Figure 49 Age Specific Incidence Rates of Thyroid cancer in Sri Lanka, 2022	70
Figure 50: Age Standardized Incidence Rates of Thyroid cancer in Sri Lanka, 2005-2022	70
Figure 51: Age Specific Incidence Rates of Lymphoma in Sri Lanka, 2022	73
Figure 52: Age Standardized Incidence Rates of Lymphoma in Sri Lanka, 2011-2022	73
Figure 53: Age Specific Incidence Rates of Leukaemia in Sri Lanka, 2022	76
Figure 54: Age Standardized Incidence Rates of Leukemia in Sri Lanka, 2011-2022	76
Figure 55: Clinical staging at the point of diagnosis of breast cancer	77
Figure 56: Clinical staging at the point of diagnosis of cervical cancer	77
Figure 57: Clinical staging at the point of diagnosis of lip, tongue and mouth cancer	77
Figure 58: Basis of diagnosis of cancer in Sri Lanka, 2022	78
Figure 59: Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2022	79
Figure 60: Cancer incidence data by districts among males in Sri Lanka, 2022	96
Figure 61: Cancer incidence data by districts among females in Sri Lanka, 2022	101
Figure 62: Crude Death Rates due to cancer in Sri Lanka based on Vital Registration System, 2001-2020	108
Figure 63: Age Standardized Death Rates due to cancer based on Vital Registration System, 2001-2020	108
Figure 64: Proportion of leading cancer deaths among males based on deaths reported to Vital Registration System of Sri Lanka, 2020	110
Figure 65: Proportion of leading cancer deaths among females based on deaths reported to Vital Registration System of Sri Lanka, 2020	110
Figure 66: Age Standardized Mortality Rates due to cancer of Trachea, bronchus and lung	111
Figure 67: Age Standardized Mortality Rates due to cancer of Lip, oral cavity and pharynx	111
Figure 68: Age Standardized Mortality Rates due to cancer of Breast	112
Figure 69: Age Standardized Mortality Rates due to cancer of Liver and intrahepatic bile ducts	112
Figure 70: Age Standardized Mortality Rates due to cancer of Oesophagus	112
Figure 71: Age Standardized Mortality Rates due to cancer of Cervix uteri	113
Figure 72: Age Standardized Mortality Rates due to cancer of Colon, rectum and anus	113
Figure 73: Age Standardized Mortality Rates due to cancer of Prostate	113

Message from the Director General of Health Services



I am happy to send this message to the 24th publication of 'Cancer Incidence and Mortality Data Sri Lanka – 2022' published by the National Cancer Control Programme, Ministry of Health & Mass Media.

The information on cancer incidence and mortality generated through the National Cancer Registry Programme is important for planning, implementing and monitoring cancer control programme in the country. Therefore, the information needs to be carefully interpreted at all levels of care. Also, ensuring timeliness and quality of cancer registry data is utmost importance for promotion of information utilization for public health initiatives and cancer care.

I appreciate the contributions of all stakeholders who involved in cancer registration process at different levels despite their other work commitments. Also, contributions of the officials involved in Indoor Morbidity and Mortality Returns and Vital Registration System is acknowledged for generation of cancer mortality data.

Dr. Asela Gunawardena

Director General of Health Services

Message from Deputy Director General (Non- Communicable Diseases)



It is with great pleasure I am sending this message to the 24th publication of 'Cancer Incidence & Mortality Data Sri Lanka-2022'. This publication describes the burden of cancer in the country in the respective year. That information is utilized by the health planners, clinicians, public health practitioners, researchers and academia.

The point of diagnosis, point of treatment and point of death of cancer patients are the data generating points for the National Cancer Registry Programme. In addition to the cancer surveillance information through the health care institutions, Vital Registration System provides additional information to complete the picture of cancer burden in relation to cancer incidence and mortality.

Since there is a delay in generating the publications of National Cancer Registry, the reasons need to be identified carefully and respective solutions need to be implemented. Also, National Cancer Control Programme should closely monitor the progress of cancer registration to expedite the whole process. Also, strong collaborations are required between health information systems and Vital Registration Systems.

I take this opportunity to thank all the stakeholders for their contributions for the National Cancer Registry Programme.

Dr. Champika Wickramasinghe

Deputy Director General (Non- Communicable Diseases)

Foreword



National Cancer Control Programme of Ministry of Health would like to release the 24th edition of National Cancer Registry Programme publication named 'Cancer incidence & Mortality Data Sri Lanka-2022'. This publication describes the burden of cancer in the country in terms of incidence and mortality.

I would like to request policy makers, health planners, clinical practitioners, public health practitioners, academia, researchers and general public to maximally utilize the information in this publication for further improvement of cancer control activities in the country. I also appreciate critical review of this publication for further improvement (of cancer registry publication) in the future.

The technical assistance and guidance given by WHO country office, WHO IARC Regional Hub for Cancer Registration in Mumbai, India are highly appreciated. Also, the collaboration with Vital Strategies to strengthen Population Based Cancer Registries initiatives in selected districts contributed numerous ways to strengthen the National Cancer Registry Programme, too.

I would like to thank cancer treatment centres, pathology laboratories, OMF units for provision of cancer incidence data. Also, the contributions of Indoor Morbidity and Mortality Returns and Civil Registration System are acknowledged. Finally, the hard work of staff of National Cancer Control Programme is appreciated.

Dr. Sudath Samaraweera

Director (Cover Up)

National Cancer Control Programme

List of Contributors

Data entry to 'CanReg5' at hospital level

Medical Officers / Nursing Officers / Development Officers at the cancer treatment centres, Pre interns
Dental surgeons / Nursing Officers / Development Officers at the OMF Units

Pathology laboratory surveillance at hospital level

Consultants / Medical Officers /Dental Surgeons / Medical Laboratory Technologists/ Development Officers /
Health Management Assistants at Histopathology / Haematology/ Oral Pathology laboratories

Data Entry & Duplicate checking at the centre

Mrs. Nimesha Prasadi Mrs. Nayomi Weerasingha

Data Coding, Duplicate Checking, Data Verification

Dr. K. G. Nirmala Jayanthi	Dr. Nirma Alpitiarachchi	Dr. Gayani Kalhari
Ms. Sachini Sashikala	Dr. J.K.Anuraddha Indiwaree	Dr. Chulaka Jayaweera

Coordination of Oral Cancer Surveillance including duplicate checking at the main database

Dr.Prasanna Jayasekara	Dr. J.K.Anuraddha Indiwaree	Dr. Asanga Abeynayaka
Dr. Tharani Rajendra	Dr. Priyanka Rajapaksha	

Statistical analysis and report writing

Dr. K.G. Nirmala Jayanthi	Dr. Nirma Alpitiarachchi	Dr. Gayani Kalhari
Dr. Suraj Perera	Dr. Dhanushka Abeygunathilaka	Dr. Kulanga Warnakulahewa
Dr. Thanuja Wickramatunga		

Cover page

Dr. Gayani Kalhari

GIS Maps

Dr.Dhanushka Abeygunathilaka Mr.Harsha Abeygunathilaka

Department of Geography, University of Colombo

Support staff

Mr. Saman Kumara Mahalekam	Mr. Amila Bandara	Mr. Nalinda Sanjeewa
Mrs. Thushari Dammika	Mr. Roshan Madumal	Mr. Ajith Wanaguru
Mrs. Deepa Pathmanjali	Mr. Saman Anuruddha	Ms. Ashoka Dilrukshi

Principal Investigator

Dr. Suraj Perera

Contribution of current Director (Cover up), NCCP Dr. Shreeni Alahapperuma and entire NCCP team is acknowledged.

Acknowledgement

National Advisory Committee on Prevention & Control of Cancers

Technical Advisory Committee on Cancer Registration & Research

World Health Organization - Country Office, Sri Lanka

All government cancer treatment centers

Oral and Maxillo - Facial surgery units

All pathology laboratories

Private hospitals

Sri Lanka College of Oncologists

Ceylon College of Pathologists

Sri Lanka College of Haematologists

Association of Oral Pathology & Oral Medicine

College of Oral Medicine & Oral Pathology

Vital Strategies Inc.

Executive Summary

Cancer Incidence and Mortality Data, Sri Lanka – 2022’ is the 24th publication on cancer surveillance data in Sri Lanka. This publication is based on the newly reported cancers in the year 2022. The newly detected cancers in year 2022 at the point of diagnosis (histopathology, haematology, oral pathology laboratories) and at the point of treatment (cancer treatment centers, Oral and Maxillo Facial surgery units) throughout the country were considered for this publication. All the data were entered into the ‘CanReg 5’ central data base. Quality checks were conducted and duplicate entries were eliminated. Analysis was done using ‘CanReg 5’ and SPSS software. For cancer mortality data, since cause specific death data for year 2022 is not yet published by the Registrar General’s Department, cause specific data of year 2020 and hospital mortality data received from Medical Statistics Unit, Ministry of Health for year 2022 were analyzed.

In the year 2022, a total number of 35,855 patients were newly diagnosed with cancer, giving crude incidence rate (CR) of 161.6 per 100,000 population. Crude incidence rate of males and females were 152.7/100,000 and 170.1/100,000 respectively. The highest 5-year age specific incidence rates were reported among males and females of 70-74 year age group (Males 1323.1/100 000 and females 900.1 /100 000). When age standardized incidence rates (ASR) were considered, the overall ASR was 143.7/100 000 and the ASR for males and females were 144.0/100 000 and 145.0/100 000.

Lip, tongue and mouth (n=3013, CR= 28.1/100 000), Colon and rectum (n= 1564, CR= 14.6/100 000), Trachea, bronchus and lung cancers (n=1381, CR 12.9/100 000), Prostate (n= 1226, CR= 11.4/100 000) and Oesophagus (n=1178, CR = 11.0/100 000) and were the highest incident cancers among males in year 2022. Out of all male cancers, 18 % were lip, tongue and mouth cancers.

Breast (n= 5447, CR= 487.6/100 000), Thyroid (n=2369, CR= 20.7/100 000), Colon and Rectum cancers (n= 1519, CR= 13.3/100 000), Uterus (n= 1238, CR= 10.8/100 000) and Cervix uteri (n=1226, CR=10.7/100 000) were the highest incident cancers among females in year 2022. Out of all female cancers 28% were breast cancers.

Cumulative rate of developing cancer between the age group of 0-74 years males is 18.5% and females is 17.3%. It means that among 1 in 5.4 males and 1 in 5.8 females have risk of developing cancer during their life time.

Staging information was available for 41% breast cancers, 30% cervical cancers and 30% lip tongue and mouth cancers. Among those with staging information 32.4% breast cancers, 65.6% cervical cancers and 72.9% lip, tongue and mouth cancers were diagnosed at the advanced stages (Stage III and IV).


There were 940 cases (male 499, female 441) of childhood and adolescent cancers (age between 0-19 Years) and 31% were leukaemias.

Out of all cancers 96.7 % were diagnosed microscopically and histopathology details were available for 90.6% cancers.

Highest number of cancers were reported from Colombo (n=3790, CR=152.9), Gampaha (n=2725, CR=111.7), Kurunegala (n=2712, CR=155.6), Kandy (n=1675, CR= 111.7) and Rathnapura (n=1609, CR=134.9) districts.

A total of 5,734 deaths were occurred due to cancers at government hospital settings in year 2022 according to the information received from Medical Statistics Unit of Ministry of Health.

CANCERS : SRI LANKA, 2022



LEADING CANCER SITES BY SEX IN SRI LANKA , 2022

Lip, tongue & mouth



Colon & rectum



Trachea, bronchus & lung



Prostate



Oesophagus



Breast



Thyroid



Colon & rectum




Uterus




Cervix Uteri





Crude Incidence Rates of five common male cancers
2005 - 2022




Crude Incidence Rates of five common
female cancers 2005 - 2022

Childhood Cancers: Sri Lanka 2022




BOYS
499



GIRLS
441

**940 CHILDREN (0-19)
WERE DIAGNOSED
WITH CANCER
IN 2022**

Common Cancer (Childhood Cancer)	Cases	
	Cases	%
Leukaemia	290	30.9
CNS Neoplasm	104	11.1
Bone	94	10
Lymphoma	91	9.7
Germ Cell tumours	65	6.9



Number of cases of Childhood cancers 2005 - 2022

Cancer Incidence and Mortality Data Sri Lanka – 2022

1.Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates the National Cancer Registry Programme in Sri Lanka with the active participation of several stakeholders for cancer registration including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) surgery units, Medical Statistics Unit, professional colleges, WHO country office etc. In addition, Registrar General's Department and Department of Census and Statistics actively contribute to cancer mortality data.

The process of surveillance of cancers is technically guided by National Advisory Committee on Prevention & Control of Cancers and the Technical Advisory Committee on Cancer Registration & Research. Also, the technical support for cancer registration is received through the International Agency for Research on Cancer (IARC) of World Health Organization (WHO) and WHO IARC Regional Hub for Cancer Registration, Mumbai, India. In addition, technical guidance is received through the Vital Strategies through the Population Based Cancer Registry initiative.

The information based on surveillance of cancers is published as 'Cancer Incidence & Mortality Data Sri Lanka-2022'. To date 23 volumes have been published. The current publication is the 24th edition of 'Cancer Incidence & Mortality Data Sri Lanka-2022'.

2. Methodology

Process of cancer registration




Figure 1: Flow diagram of the process of cancer registration in Sri Lanka

2.1 Collection of cancer incidence and mortality data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) Surgery units throughout the country.

2.1.1 Newly registered cancer patients at the cancer treatment centres

The patient details and tumour details of newly registered cancer patients were extracted from 25 government cancer treatment centres (table 1). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form - H 1256'. Medical officers, nursing officers or development officers attached to the cancer treatment centres actively involved in documenting or extracting relevant cancer incidence data. In some centres, trained pre-intern medical graduates who were temporarily recruited through WHO Biennium funds extracted from the cancer patients' clinic records. The extracted data were entered into the 'CanReg 5', data base at the cancer treatment centre.

Table 1: Distribution of government cancer treatment centres in year 2022

Category of hospital	Name of the hospital
National Hospitals	Apeksha Hospital - Maharagama (National Cancer Institute), National Hospital Kandy
Teaching Hospitals	Colombo North Teaching Hospital, Karapitiya, Anuradhapura, Batticaloa, Rathnapura, Kurunegala, Badulla, Kalutara
District General Hospitals	Gampaha, Avissawella, Nuwaraeliya, Matale, Matara, Hambantota, Polonnaruwa, Vavuniya, Chilaw, Trincomalee, Ampara, Kegalle, Moneragala, Embilipitiya
Base Hospital	Tellippalai (Jaffna)

Data entering process was closely monitored by the cancer registry staff of National Cancer Control Programme and random checks were conducted to ensure data accuracy and quality. Final data sheet was received from each cancer centre as an Excel CSV file.

After the quality assessment, the excel sheet was arranged according to the required format for uploading to CanReg5. Then excel sheets were uploaded to a standalone CanReg5 data base. From the stand alone CanReg5 data base, Patient, Tumour & Source files were generated separately in. tsv format. Patient, tumour, source files were uploaded to 'Rupantharan' software. Through the 'Rupantharan' software cancer incidence data were uploaded to the central cancer registry database.

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 68 Histopathology laboratories, 34

Haematology laboratories and 3 oral pathology laboratories have passively sent relevant data for the year 2022 (Table 2).

Table 2: Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2022

Category of hospital	Type of Pathology laboratory		
	Histopathology	Haematology	Oral Pathology
National Hospital	National Hospital of Sri Lanka, National Hospital of Kandy, National Eye Hospital, National Hospital for Respiratory Diseases-Welisara	National Hospital of Kandy	National Dental Hospital
Teaching Hospitals	De Soysa Hospital for Women, Castle Hospital for Women, Lady Ridgeway Hospital, Colombo South, Colombo North, Sri Jayawardenapura, Karapitiya, Rathnapura, Anuradhapura, Peradeniya, SBCH, Batticaloa, Jaffna, Kuliyaipitiya, Kotalawala Defence University Hospital, Kalutara, Badulla, Kurunegala	Lady Ridgeway Hospital, Colombo South, Colombo North, Karapitiya, Sri Jayawardenapura, Rathnapura, SBCH, Kurunegala, Kuliyaipitiya, Anuradhapura, Peradeniya, Batticaloa, Kotalawala Defence University Hospital, Badulla	Karapitiya
District General Hospitals	Avissawella, Gampaha, Negombo, Matara, Hambanthota, Kegalle, Embilipitiya, Chilaw, Polonnaruwa, Nawalapitiya, Matale, Nuwaraeliya, Ampara, Trincomalee, Vavuniya, Kilinochchi, Mannar	Negombo, Avissawella, Hambanthota, Embilipitiya, Nuwaraeliya, Matale, Mannar, Polonnaruwa	
Base Hospital	Homagama, Mulleriyawa, Wathupitiwala, Panadura, Balapitiya, Elpitiya, Tangalle, Kamburupitiya, Embilipitiya, Kahawatta, Balangoda, Puttlam, Gampola, Rikillagaskada, Dambulla, Diyathalawa, Mahiyanganaya, Karawanella, Thambuttegama, Ashroff Memorial Hospital – Kalmunai, Horana	Wathupitiwala, Panadura, Horana, Homagama, Balapitiya, Elpitiya, Tangalle, Puttlam, Embilipitiya, Gampola	

Category of hospital	Type of Pathology laboratory		
	Histopathology	Haematology	Oral Pathology
University Units	Faculty of Medicine – Colombo, Ruhuna, Sri Jayawardanepura, Ragama	Sri Jayawardanepura	Faculty of Dental Sciences– Peradeniya
Private Sector	Kings Hospital - Colombo, Asiri Hospital - Colombo, Asiri Hospital- Kandy, Hemas Hospital - Colombo		

Most of the pathology laboratories send the data as a paper-based reports. The reported cancers were coded by the cancer registry staff of NCCP and entered into the central CanReg5 database at the NCCP. According to the instructions of International Classification of Diseases for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer.

Some returns were received as an Excel sheet and NCCP staff coded and uploaded into the main CanReg5 database via ‘Rupantharan’ software.

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

In year 2022/2023 through Primary Health Care Strengthening Project funds CanReg5 data base was introduced to each OMF Unit. Staff was also trained on CanReg5 data base handling. From year 2022, details of newly registered oral cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received through CanReg5 database in 34 centres (Table 3).

Table 3: Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2022

Category of hospital	Name of the hospital
National Hospital	Kandy, Dental Institute - Colombo
Teaching Hospitals	Colombo South, Colombo North, Karapitiya, Rathnaura, Anuradhapura, Jaffna, Kuliypitiya, Kurunegala, Batticaloa, Badulla
District General Hospitals	Ampara, Gampaha, Kalutara, Chilaw, Polonnaruwa, Hambantota, Matara, Nuwara Eliya, Trincomalee, Embilipitiya, Kegalle, Negombo, Vavuniya, Avissawella, Matale, Killinochchi, Mannar, Diyathalawa
Base Hospital	Panadura, Tangalle, Elpitiya
University Units	Faculty of Dental Sciences, Peradeniya

The newly diagnosed cancers at the OMF units were reported to the NCCP as paper-based reports. Reported cancers were coded by the cancer registry staff of NCCP and entered into the central CanReg5 database at the NCCP via 'Rupantharan' software.

2.2 Cancer mortality data

Mortality data due to cancer were obtained through the (i) Annual Health Bulletin based on Indoor Morbidity Mortality Return (IMMR) from the hospital statistics and (ii) Department of Census & Statistics website based on data derived from the Vital Registration System of Sri Lanka. Additional analysis was conducted based on aggregated data to generate respective descriptive data tables and graphs.

In addition to that, details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form - 3 for the Population Based Cancer Registry, Colombo district. A total of 47 divisional death registrars has sent relevant details for the year 2022. That information was also incorporated to the National Cancer Registry database.

2.3 Duplicate checking & verification of data

Since National Cancer Registry - Sri Lanka extracts data on cancer incidence from multiple sources, occurrence of duplicates is inevitable. Therefore, while entering and confirming the data to the CanReg5 data base, duplicate checking was conducted using 'Person search' option of the CanReg5. In addition to the duplicate checking done through CanReg5, further duplicates were identified and removed using MS Excel and Linkpro software.

After removing possible duplicates, consistency checking and verification was conducted in using MS Excel and 'IARCcrg' software.

Mismatches according to;

- Age/Incidence and Birthdates
- Age/Site/Histology
- Site/Histology
- Sex/Site
- Sex/Histology
- Behaviour/Site
- Behaviour/Histology
- Grade/Histology Basis of Diagnosis/Histology

To ensure reliability of data, the mismatching data was crosschecked with original data source and corrected. Data sources up to the patient clinic files were rechecked in instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.4 Analysis of registry data & dissemination of information

Data analysis was conducted using CanReg5 software package, SPSS and MS Excel. The standard cancer registry tables described at the CI 5 were generated through CanReg5 database. The frequency distribution of cancers and their percentages and age-specific incidence rates were calculated using MS Excel and SPSS software version 22. The final report will be disseminated as 'Cancer Incidence & Mortality Data Sri Lanka-2022'.

Population estimates used for incidence rate calculations are given in table 4 & 5.

Table 4: Estimated mid-year population by 5-year age groups in Sri Lanka, 2022

Age group	Male	Female	Total
0-4	960,834	944,999	1,905,833
5-9	962,990	945,113	1,908,103
10-14	904,842	885,487	1,790,329
15-19	894,466	899,492	1,793,958
20-24	808,374	861,457	1,669,831
25-29	810,120	882,535	1,692,655
30-34	868,088	918,182	1,786,270
35-39	747,184	787,435	1,534,619
40-44	720,106	759,162	1,479,268
45-49	672,961	726,648	1,399,609
50-54	632,772	694,231	1,327,002
55-59	545,054	612,717	1,157,772
60 - 64	462,581	535,075	997,656
65 - 69	308,129	379,173	687,302
70 - 74	197,407	249,974	447,381
75+	243,612	359,789	603,401
Total	10,739,520	11,441,467	22,180,988

Source- Department of Census and Statistics

Table 5: Estimated mid-year population by the district in Sri Lanka 2022

District	Male	Female	Total
Colombo	1,215,825	1,262,097	2,477,923
Gampaha	1,181,942	1,257,127	2,439,069
Kalutara	625,134	666,769	1,291,903
Kandy	714,813	784,355	1,499,168
Matale	255,672	274,511	530,183
Nuwara Eliya	374,280	408,315	782,595
Galle	549,745	596,676	1,146,421
Matara	418,465	455,216	873,681
Hambantota	334,570	346,411	680,981
Jaffna	295,196	333,457	628,653
Mannar	66,367	68,680	135,047
Vavuniya	57,905	57,285	115,190
Mulativu	96,277	99,329	195,606
Killinochchchi	49,473	49,651	99,124
Batticaloa	280,656	308,887	589,543
Ampara	365,135	389,177	754,312
Trincomalee	219,216	224,591	443,807
Kurunagala	836,725	905,695	1,742,420
Puttalam	411,371	438,635	850,006
Anuradhapura	467,330	489,995	957,325
Pollonnaruwa	222,148	227,158	449,306
Badulla	432,200	466,945	899,145
Moneragala	252,673	255,741	508,414
Rathnapura	587,980	604,647	1,192,627
Kegalle	428,422	470,117	898,539
Total	10,739,520	11,441,467	22,180,988

Source- Department of Census and Statistics

Cancer Incidence Data of Sri Lanka – 2022

Population Sri Lanka 2022

Population - 22, 181, 000




Figure 2: Population pyramid of Sri Lanka in 2022 by 5-year age groups

Table 6: Cancer Incidence by sex in Sri Lanka, 2005-2022

Year	Sex	No.	%	CR	ASR
2005	Male	6,058	45.3	62.3	68.1
	Female	7,313	54.7	73.4	73.4
	Total	13,372		67.9	70.6
2006	Male	6,205	44.1	62.7	69.2
	Female	7,875	55.9	79.0	79.5
	Total	14,080		70.9	74.2
2007	Male	6,356	46.6	63.8	70.9
	Female	7,279	53.4	72.2	72.8
	Total	13,635		68.0	71.6
2008	Male	7,695	46.6	76.5	85.5
	Female	8,816	53.4	86.6	88.0
	Total	16,511		81.6	86.4
2009	Male	7,858	46.5	77.4	86.4
	Female	9,030	53.5	87.7	89.1
	Total	16,888		82.6	87.5
2010	Male	7993	47.1	78.0	87.4
	Female	8970	52.9	86.2	87.7
	Total	16963		82.1	87.3
2011	Male	8370	47.8	80.6	90.4
	Female	9112	52.1	86.7	88.7
	Total	17482		83.7	89.2
2012	Male	11363	49.1	115.3	107.8
	Female	11773	50.9	112.1	95.5
	Total	23136		113.6	100.1
2013	Male	11364	48.2	114.0	106.3
	Female	12167	51.8	114.6	97.4
	Total	23531		114.3	100.7
2014	Male	12021	47.6	119.5	112.0
	Female	13250	52.4	123.6	105.3
	Total	25271		121.6	107.3
2015	Male	13921	48.1	137.1	128.6
	Female	15046	51.9	139.1	118.8
	Total	28967		138.1	122.0
2016	Male	16,533	48.4	161.1	151.2
	Female	17,646	51.6	161.3	137.4
	Total	34,179		161.2	142.0
2017	Male	15,458	48.1	148.9	140.2
	Female	16,712	51.9	151.1	128.8
	Total	32,170		150.0	132.7
2018	Male	14,917	48.3	142.2	133.6
	Female	15,936	51.7	142.6	121.1
	Total	30,853		142.4	125.8
2019	Male	14855	46.6	140.6	132.6
	Female	16994	53.4	151.1	128.8
	Total	31849		146.0	128.9
2020	Male	17,451	46.4	164.4	155.3
	Female	20,197	53.6	178.6	152.2
	Total	37,648		171.8	152.3
2021	Male	17,582	46.6	163.9	155.1
	Female	20,171	53.4	176.5	150.4
	Total	37,753		170.4	151.3
2022	Male	16,398	45.7	152.7	144.9
	Female	19,457	54.3	170.1	145.0
	Total	35,855		161.6	143.7




Figure 3:Crude Cancer Incidence Rates of Sri Lanka, 2005-2022




Figure 4: Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2022




Figure 5: Cancer Incidence Rates of Sri Lanka in 2022

Table 7: Cancer Incidence by 5-year age groups and sex in Sri Lanka, 2022

Age group	Male			Female			Total		
	Cases	Population	Age sp. Incidence rate	Cases	Population	Age sp. Incidence rate	Cases	Population	Age sp. Incidence rate
Unknown	17			11			28		
00-04	151	960,834	15.7	117	944999	12.4	268	1905833	14.1
05-09	102	962,990	10.6	82	945113	8.7	184	1908103	9.6
10-14	117	904,842	12.9	103	885487	11.6	220	1790329	12.3
15-19	129	894,466	14.4	139	899492	15.5	268	1793958	14.9
20-24	156	808,374	19.3	218	861457	25.3	374	1669831	22.4
25-29	175	810,120	21.6	358	882535	40.6	533	1692655	31.5
30-34	247	868,088	28.5	483	918182	52.6	730	1786270	40.9
35-39	302	747,184	40.4	868	787435	110.2	1170	1534619	76.2
40-44	598	720,106	83.0	1362	759162	179.4	1960	1479268	132.5
45-49	819	672,961	121.7	1714	726648	235.9	2533	1399609	181.0
50-54	1369	632,772	216.3	2064	694231	297.3	3433	1327002	258.7
55-59	1950	545,054	357.8	2326	612717	379.6	4276	1157772	369.3
60-64	2630	462,581	568.5	2717	535075	507.8	5347	997656	536.0
65-69	2669	308,129	866.2	2541	379173	670.1	5210	687302	758.0
70-74	2612	197,407	1323.2	2250	249974	900.1	4862	447381	1086.8
75+	2355	243,612	966.7	2104	359789	584.8	4459	603401	739.0
Total	16398	10739520	152.7	19457	11441467	170.1	35855	22180988	161.6




Figure 6: Age Specific Cancer Incidence Rates in Sri Lanka, 2022

Table 8: Leading cancer site by sex in Sri Lanka, 2022

Male					Female				
ICD code	Site	No	CR	ASR	ICD code	Site	No	CR	ASR
C00-C06	Lip, tongue and mouth	3013	28.1	26.1	C50	Breast	5447	47.6	40.3
C18-C20	Colon and rectum	1564	14.6	13.8	C73	Thyroid	2369	20.7	18.4
C33-C34	Trachea, bronchus and lung	1381	12.9	12.3	C18-C20	Colon and rectum	1519	13.3	11.0
C61	Prostate	1226	11.4	11.1	C54-C55	Uterus	1238	10.8	9.2
C15	Oesophagus	1178	11.0	10.4	C53	Cervix uteri	1226	10.7	8.9
C09-C14	Pharynx	877	8.2	7.6	C56	Ovary	1112	9.7	8.4
C81-C85, C96	Lymphoma	601	5.6	5.3	C15	Oesophagus	805	7.0	5.7
C32	Larynx	600	5.6	5.3	C00-C06	Lip, tongue and mouth	792	6.9	5.7
C67	Bladder	573	5.3	5.1	C33-C34	Trachea, bronchus and lung	553	4.8	4.1
C73	Thyroid	560	5.2	4.8	C81-C85, C96	Lymphoma	428	3.7	3.3
All sites		16398	152.7	144.9	All sites		19457	170.1	145.0




Figure 7: Proportion of leading cancers in males in Sri Lanka, 2022




Figure 8: Proportion of leading cancers in females in Sri Lanka, 2022

Crude incidence rates of leading cancers in Sri Lanka, 2022




Figure 9: Crude incidence rates of leading cancers in males in Sri Lanka, 2022




Figure 10: Crude incidence rates of leading cancers in females in Sri Lanka, 2022

Leading cancers of Sri Lanka according to age group in 2022

00 – 14 year age group




Figure 11: Leading cancers by 00–14 year age group among males in Sri Lanka, 2022




Figure 12: Leading cancers by 00–14 year age group among females in Sri Lanka, 2022

15 – 34 year age group




Figure 13: Leading cancers by 15–34 year age group among males in Sri Lanka, 2022




Figure 14: Leading cancers by 15–34 year age group among females in Sri Lanka, 2022

35 – 49 year age group




Figure 15: Leading cancers by 35–49 year age group among males in Sri Lanka, 2022




Figure 16: Leading cancers by 35–49 year age group among females in Sri Lanka, 2022

50 – 64 year age group




Figure 17: Leading cancers by 50–64 year age group among males in Sri Lanka, 2022




Figure 18: Leading cancers by 50–64 year age group among females in Sri Lanka, 2022

65 year and above age group




Figure 19: Leading cancers by 65 year and above age group among males in Sri Lanka, 2022




Figure 20: Leading cancers by 65 year and above age group among females in Sri Lanka, 2022

Table 9: Number of cancers by 5-year age groups and ICD 10 site, among males in Sri Lanka, 2022

ICD 10 Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	UK	Total
C00 - Lip	0	1	0	0	0	0	1	2	2	5	9	26	21	12	24	20	0	123
C01 - Base of tongue	0	0	0	0	0	0	1	3	6	17	37	43	48	38	31	21	0	245
C02 - Tongue other	0	0	0	0	1	3	12	21	44	58	112	130	131	122	70	76	0	780
C03 - Gum	0	0	0	0	0	0	0	0	3	7	9	10	18	25	24	14	0	110
C04 - Floor of mouth	0	0	0	0	0	1	0	1	4	11	30	48	36	41	10	23	1	206
C05 - Palate	1	1	0	1	3	1	2	5	3	21	46	31	57	47	37	35	0	291
C06 - Oral cavity	0	1	0	0	0	4	5	20	62	97	127	195	173	209	185	178	2	1258
C07 - Parotid gland	1	0	1	2	2	1	2	4	10	4	6	13	14	12	10	7	0	89
C08 - Other salivary gland	0	0	0	0	0	0	1	2	2	5	6	7	10	7	7	4	0	51
C09 - Tonsil	0	0	0	0	0	0	0	2	5	8	18	46	35	31	23	25	1	194
C10 - Oropharynx	0	0	0	0	0	0	2	0	3	11	29	42	39	39	26	17	0	208
C11 - Nasopharynx	0	0	2	1	0	1	1	1	3	4	3	5	6	5	1	1	0	34
C12 - Pyriform sinus	0	0	0	0	0	0	0	1	4	4	15	40	43	36	33	23	0	199
C13 - Hypopharynx	0	0	0	0	0	0	0	0	2	4	11	14	21	12	16	20	0	100
C14 - Oter ill-defined site of oral cavity and pharynx	0	0	0	0	0	0	0	0	1	11	8	31	25	20	22	24	0	142
C15 - Oesophagus	0	0	0	0	2	1	1	9	9	41	98	173	224	204	220	196	0	1178
C16 - Stomach	0	0	0	0	2	1	3	4	11	14	30	39	61	57	64	54	0	340
C17 - Small intestine	0	0	0	0	0	1	1	1	2	2	7	9	10	12	8	6	0	59
C18 - Colon	0	0	1	0	3	9	9	18	31	29	77	72	109	125	138	101	1	723
C19 - Rectosigmoid junction	0	0	0	0	1	0	1	2	4	8	8	12	17	19	19	20	0	111
C21C20 - Rectum	0	0	0	0	1	2	8	8	37	39	62	99	101	139	116	118	0	730
C21 - Anus and anal canal	0	0	0	0	0	0	1	1	2	4	5	7	15	14	10	19	0	78
C22 - Liver and intrahepatic bile ducts	4	0	0	0	4	0	4	2	6	12	16	47	78	108	89	61	1	432
C23 - Gallbladder	0	0	0	0	2	0	0	0	1	2	5	4	6	4	6	7	0	37
C24 - Other ill-defined site of bile tract	0	0	0	0	0	1	0	0	4	0	5	11	11	10	14	9	0	65
C25 - Pancrease	0	0	0	0	1	0	1	0	3	6	9	10	24	18	11	11	0	94
C26 - Other part of digestive system	0	0	0	0	1	0	0	0	0	8	2	9	11	5	15	3	0	54
C30 - Nasal cavity and middle ear	0	0	0	0	0	0	1	3	1	4	5	4	10	9	6	4	0	47
C31 - Accessory sinuses	0	0	1	0	0	0	0	3	1	2	7	8	2	5	9	2	0	40
C32 - Larynx	0	0	0	0	1	1	1	1	6	41	52	76	108	105	118	90	0	600
C33 - Trachea	0	0	0	0	0	0	0	0	0	1	0	0	3	3	3	0	0	10
C34 - Bronchus and lung	0	0	0	0	4	7	9	9	18	42	92	171	300	298	245	173	3	1371
C37 - Thymus	0	0	0	0	0	2	3	0	5	3	2	6	1	1	1	1	0	25
C38 Heart, mediastinum and pleura	0	0	2	3	2	1	6	2	2	2	5	5	5	1	4	3	0	43
C39 Other part of respiratory tract	0	0	0	0	0	0	1	0	0	0	2	0	2	1	2	1	0	9
C40 - Bones limb	1	1	3	7	9	2	1	4	2	1	0	1	5	2	4	2	0	45
C41 - Bones unspecified site	2	9	19	17	3	1	2	3	4	2	2	3	6	6	3	4	0	86
C43 - Melanoma of Skin	0	0	0	0	1	0	0	1	0	0	1	4	4	5	6	7	0	29
C44 - Skin other	0	0	0	0	0	4	6	4	12	10	26	29	42	28	45	65	0	271
C45 - Mesothelioma	0	0	0	0	0	2	0	0	0	0	0	0	4	1	1	0	0	8
C47 - Peripheral nerves and autonomic nervous system	2	1	1	2	0	0	1	1	0	0	2	2	1	3	2	0	0	18
C48 - Retroperitoneum and peritoneum	0	0	0	0	1	0	0	0	2	2	2	1	1	2	2	0	0	13
C49 - Connective, subcutaneous and other soft tissue	5	5	10	6	5	6	6	4	4	4	10	6	18	13	16	15	1	134

ICD 10 Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	UK	Total
C50 - Breast	0	0	0	0	1	0	3	9	14	16	25	20	23	29	25	23	0	188
C60 - Penis	1	0	0	0	0	0	0	3	4	2	6	10	15	19	15	12	0	87
C61 - Prostate	0	0	0	1	0	1	1	0	3	3	30	57	150	241	338	399	2	1226
C62 - Testis	1	1	1	6	6	16	12	5	8	5	4	5	7	3	2	3	0	85
C63 - Other and unspecified female genital organs	1	1	0	0	0	0	0	0	0	0	2	3	5	1	1	2	0	16
C64 - Kidney	12	1	0	0	0	2	2	12	20	22	37	42	50	32	54	20	1	307
C65 - Renal pelvis	0	0	0	0	0	0	0	0	0	1	1	1	3	4	3	2	0	15
C66 - Ureter	0	0	0	0	0	0	0	0	0	0	1	0	3	1	1	0	0	6
C67 - Bladder	0	0	0	0	0	1	5	4	12	14	24	57	90	120	117	128	1	573
C68 - Other and unspecified urinary organs	0	0	0	0	0	0	0	0	1	1	1	3	3	2	4	1	0	16
C69 - Eye and adnexa	15	4	0	0	1	0	0	0	4	1	1	4	0	7	3	7	0	47
C70 - Meninges	1	0	0	1	1	0	0	0	1	2	0	2	1	3	1	0	0	13
C71 - Brain	5	17	15	11	10	17	11	12	20	19	31	28	34	24	19	5	0	278
C72 - Other parts of central nervous system	2	2	1	1	1	0	1	0	2	0	2	1	2	1	3	0	0	19
C73 - Thyroid gland	0	0	5	11	31	30	51	48	83	65	41	40	63	37	37	18	0	560
C74 - Adrenal gland	10	2	0	0	2	1	0	0	1	1	0	3	2	3	2	0	0	27
C75 - Other endocrine glands	1	3	2	1	0	2	0	1	0	0	2	3	4	1	0	0	0	20
C76 - Other and ill-defined site	1	0	1	1	0	2	1	2	7	7	13	9	20	16	20	14	1	115
C77 - Lymph nodes	0	0	0	0	1	1	4	2	2	6	7	4	12	13	8	11	0	71
C80 - Unknown primary	3	1	5	1	5	8	9	10	22	28	59	69	115	109	115	117	0	676
C81 - Hodgkin lymphoma	1	1	5	11	13	12	11	12	8	8	9	9	14	7	17	11	1	150
C82 - Follicular lymphoma	0	0	0	2	0	0	4	0	2	2	6	4	8	9	2	4	0	43
C83 - Non follicular lymphoma	1	6	3	4	3	2	2	3	6	6	5	6	6	10	7	4	0	74
C84 - Mature T/NK-cell lymphoma	3	1	3	2	0	3	2	1	0	4	0	2	1	1	1	2	1	27
C85 - Other and unspecified type of non-Hodgkin lymphoma	0	3	0	7	10	14	12	9	20	23	18	25	46	42	33	35	0	297
C86 - Other specified type of T/NK-cell lymphoma	0	0	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	4
C88 - Malignant immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	2	2	0	1	3	0	0	8
C90 - Multiple myeloma and malignant plasma cell disease	0	0	0	0	2	0	0	0	6	8	15	22	48	36	37	33	0	207
C91 - Lymphoid leukaemia	48	34	28	13	5	5	4	4	5	6	5	5	11	3	3	2	0	181
C92 - Myeloid leukaemia	12	3	6	10	9	1	12	14	17	16	17	14	21	16	29	16	0	213
C93 - Monocytic leukaemia	3	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	6
C94 - Other leukaemia of specified cell type	1	0	0	1	1	1	1	4	1	5	2	1	2	2	2	2	0	26
C95 - Leukaemia of unspecified cell type	6	2	2	5	3	3	5	3	3	2	2	4	3	6	3	6	0	58
C96 - Other and unspecified malignant neoplasm of lymphoid, haematopoietic and related tissue	7	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	10
D45 - Polycythaemia vera	0	0	0	0	0	0	0	0	1	0	1	2	1	2	1	0	0	8
D46 - Myelodysplastic syndrome	0	0	0	0	2	0	0	2	1	0	2	1	4	8	4	11	0	35
D47 Other neoplasm of uncertain behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	2	0	0	2	7	3	5	7	0	26
Total	151	102	117	129	156	175	247	302	598	819	1369	1950	2630	2669	2612	2355	17	16398

Table 10: Number of cancers by 5-year age groups and ICD 10 site, among females in Sri Lanka, 2022

ICD 10Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	UK	Total
C00 - Lip	0	0	1	0	1	0	0	0	0	0	4	1	7	5	9	13	0	41
C01 - Base of tongue	0	0	0	0	0	0	1	1	0	0	4	5	11	6	12	15	0	55
C02 - Tongue other	0	0	0	0	1	0	3	4	11	17	17	20	32	28	24	23	0	180
C03 - Gum	0	0	0	0	0	0	0	1	1	2	3	2	9	6	10	11	0	45
C04 - Floor of mouth	0	0	0	0	0	0	0	0	2	2	2	5	5	6	14	4	0	40
C05 - Palate	0	0	0	0	1	1	0	4	1	1	10	5	11	8	18	13	1	74
C06 - Oral cavity	0	0	0	0	1	1	1	3	7	13	28	43	60	68	65	67	0	357
C07 - Parotid gland	0	0	1	2	5	1	3	6	6	9	9	3	13	2	8	5	1	74
C08 - Other salivary gland	0	0	0	0	0	0	0	0	2	1	2	5	2	3	2	4	0	21
C09 - Tonsil	0	0	0	0	0	0	0	1	1	0	2	2	8	5	2	3	0	24
C10 - Oropharynx	0	0	0	0	0	0	0	0	1	0	2	3	1	4	4	4	0	19
C11 - Nasopharynx	0	0	0	0	2	1	0	1	1	1	2	3	0	2	1	0	0	14
C12 - Pyriform sinus	0	0	0	0	0	0	0	0	1	1	5	3	0	5	3	3	0	21
C13 - Hypopharynx	0	0	0	0	0	0	1	3	1	1	5	2	6	6	1	9	0	35
C14 - Oter ill- defined site of oral cavity and pharynx	0	0	0	0	1	0	0	0	0	1	2	4	5	5	1	4	0	23
C15 - Oesophagus	0	0	0	1	0	4	0	5	9	20	40	75	126	167	139	218	1	805
C16 - Stomach	0	0	1	0	0	2	2	5	4	15	7	24	31	36	29	36	0	192
C17 - Small intestine	0	0	0	0	0	2	3	2	1	3	6	7	6	7	6	6	0	49
C18 - Colon	0	1	1	3	3	3	12	18	30	38	79	100	110	112	128	109	1	748
C19 - Rectosigmoid junction	0	0	0	0	0	0	4	3	4	12	25	9	15	24	26	13	0	135
C21C20 - Rectum	0	0	0	0	3	1	2	9	25	39	62	105	104	85	105	95	1	636
C21 - Anus and anal canal	0	0	0	0	0	0	0	1	1	3	7	5	9	8	7	14	0	55
C22 - Liver and intrahepatic bile ducts	6	0	0	0	0	2	3	4	3	10	19	14	33	34	32	36	0	196
C23 - Gallbladder	0	0	0	0	0	0	3	3	1	0	8	8	11	15	5	10	0	64
C24 - Other ill-defined site of bile tract	0	0	0	0	1	0	0	1	4	3	1	11	12	11	3	8	0	55
C25 - Pancrease	0	0	2	0	0	0	3	5	5	11	6	14	10	26	14	17	0	113
C26 - Other part of digestive system	0	0	0	0	0	0	1	1	0	2	3	0	4	5	4	7	0	27
C30 - Nasal cavity and middle ear	0	0	0	1	1	0	1	1	2	3	0	3	6	5	5	5	0	33
C31 - Accessory sinuses	0	0	0	0	0	0	0	2	0	1	4	4	5	6	3	2	0	27
C32 - Larynx	0	0	0	0	1	0	1	2	3	2	1	8	10	7	15	13	0	63
C33 - Trachea	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	4
C34 - Bronchus and lung	0	0	1	1	7	4	4	10	19	37	62	58	80	86	99	81	0	549
C37 - Thymus	0	0	0	0	0	0	0	3	1	3	4	1	3	7	4	3	0	29
C38 Heart, mediastinum and pleura	1	1	0	2	0	1	3	1	2	1	5	0	4	0	4	4	0	29
C39 Other part of respiratory tract	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C40 - Bones limb	0	0	7	3	0	4	2	0	1	3	2	1	2	4	1	1	0	31
C41 - Bones unspecified site	7	10	12	2	2	5	4	7	2	4	5	5	4	2	5	3	0	79
C43 - Melanoma of Skin	0	0	1	0	1	0	0	0	4	2	8	4	2	9	10	10	0	51
C44 - Skin other	0	0	1	1	4	6	8	3	15	14	12	27	24	36	48	65	1	265
C45 - Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0	0	4
C47 - Peripheral nerves and autonomic nervous system	4	1	0	1	0	0	1	1	1	0	0	1	1	2	0	0	0	13
C48 - Retroperitoneum and peritoneum	0	1	0	0	1	1	0	0	2	0	2	4	3	4	5	3	0	26
C49 - Connective, subcutaneous and other soft tissue	5	2	6	1	0	5	9	9	7	8	11	14	12	9	7	10	0	115
C50 - Breast	0	0	0	0	11	37	85	233	499	667	701	781	769	653	564	446	1	5447
C51 - Vulva	0	0	0	0	0	0	1	1	0	6	3	6	5	6	11	12	0	51
C52 - Vagina	0	0	0	0	0	0	0	1	1	1	1	6	11	15	13	21	0	70

ICD 10Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	UK	Total
C53 - Cervix uteri	0	0	0	1	0	1	11	47	80	105	145	178	201	158	150	148	1	1226
C54 - Corpus uteri	0	0	0	0	4	7	11	14	32	50	101	130	210	195	135	86	1	976
C55 - Uterus NOS	0	0	0	0	3	7	3	9	11	21	20	39	42	40	46	21	0	262
C56 - Ovary	3	3	13	17	22	25	19	42	66	104	133	151	169	160	98	87	0	1112
C57 - Other female genital organs	0	0	1	0	2	0	1	2	5	4	4	8	13	6	1	1	0	48
C58 - Placenta	0	0	0	1	0	3	1	0	1	1	0	0	0	0	0	0	0	7
C64 - Kidney	9	4	0	1	0	0	2	2	6	12	13	7	20	22	20	12	0	130
C65 - Renal pelvis	0	0	0	2	0	0	1	0	2	1	0	1	1	2	2	0	0	12
C66 - Ureter	0	0	0	0	1	0	0	0	0	1	1	0	3	4	3	1	0	14
C67 - Bladder	0	0	0	1	0	2	1	7	4	5	8	18	21	28	27	39	0	161
C68 - Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0	1	0	5
C69 - Eye and adnexa	9	0	0	0	2	0	2	0	1	2	2	2	1	1	1	1	0	24
C70 - Meninges	0	0	0	1	0	0	3	3	11	6	11	5	6	1	1	1	0	49
C71 - Brain	13	20	10	6	5	9	7	12	11	13	15	16	17	15	11	9	0	189
C72 - Other parts of central nervous system	2	1	0	4	0	0	0	0	1	0	2	2	0	0	1	0	0	13
C73 - Thyroid gland	1	5	6	57	97	192	209	312	356	319	250	186	149	105	72	52	1	2369
C74 - Adrenal gland	4	0	1	0	1	0	0	0	1	0	3	2	1	2	4	0	0	19
C75 - Other endocrine glands	0	0	0	2	2	0	1	3	4	1	0	1	4	0	1	1	0	20
C76 - Other and ill-defined site	0	0	2	0	0	0	3	2	5	8	11	4	12	12	9	12	0	80
C77 - Lymph nodes	0	0	0	1	1	3	0	1	0	2	6	3	4	10	1	7	0	39
C80 - Unknown primary	0	0	2	2	4	3	12	18	31	40	75	74	98	87	86	96	1	629
C81 - Hodgkin lymphoma	0	0	1	7	10	10	9	4	5	8	5	8	16	12	5	3	0	103
C82 - Follicular lymphoma	0	0	0	0	0	2	1	4	5	2	3	4	2	3	3	2	0	31
C83 - Non follicular lymphoma	0	2	4	3	1	0	0	2	3	2	4	6	10	2	2	5	0	46
C84 - Mature T/NK-cell lymphoma	0	1	4	2	1	0	1	1	1	1	1	2	3	2	0	4	0	24
C85 - Other and unspecified type of non-Hodgkin lymphoma	0	0	1	1	6	7	10	8	14	14	21	17	31	34	24	29	0	217
C86 - Other specified type of T/NK-cell lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C88 - Malignant immunoproliferative diseases	0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	0	6
C90 - Multiple myeloma and malignant plasma cell disease	0	0	1	0	0	0	0	1	1	11	15	23	44	47	35	24	0	202
C91 - Lymphoid leukaemia	39	20	18	8	1	1	2	3	3	3	8	7	9	6	4	3	0	135
C92 - Myeloid leukaemia	7	5	3	4	5	4	10	9	11	8	12	21	22	23	28	19	0	191
C93 - Monocytic leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	3
C94 - Other leukaemia of specified cell type	1	1	1	0	0	0	1	1	0	1	2	2	3	1	0	4	0	18
C95 - Leukaemia of unspecified cell type	4	3	1	0	1	1	0	4	7	6	5	4	5	3	3	1	0	48
C96 - Other and unspecified malignant neoplasm of lymphoid, haematopoietic and related tissue	1	1	0	0	1	0	1	1	0	0	1	0	0	1	0	0	0	7
D45 - Polycythaemia vera	0	0	0	0	0	0	0	1	0	0	0	0	1	3	1	0	0	6
D46 - Myelodysplastic syndrome	0	0	0	0	0	0	0	0	1	2	5	0	10	9	4	6	0	37
D47 Other neoplasm of uncertain behaviour of lymphoid, haematopoietic tissue	0	0	0	0	0	0	0	0	1	2	0	2	1	3	3	1	0	13
Total	117	82	103	139	218	358	483	868	1362	1714	2064	2326	2717	2541	2250	2104	11	19457

Table 11: Number of cancers by 5-year age group and ICD 10 site categories among males in Sri Lanka, 2022

Cancer Registry (2022)

Population-Sri Lanka 2022																			
Cases by age group (Period) - Male																			
S I T E	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	ICD (10th)	
Lip	123	0	-	1	-	-	-	1	2	2	5	9	26	21	12	24	20	C00	
Tongue	1025	0	-	-	-	1	3	13	24	50	75	149	173	179	160	101	97	C01-02	
Mouth	1865	3	1	-	1	3	6	7	26	72	136	212	284	284	322	256	250	C03-06	
Salivary glands	140	0	1	-	1	2	1	3	6	12	9	12	20	24	19	17	11	C07-08	
Tonsil	194	1	-	1	2	-	-	-	2	5	8	18	46	35	31	23	25	C09	
Other oropharynx	208	0	-	-	-	-	-	2	-	3	11	29	42	39	39	26	17	C10	
Nasopharynx	34	0	-	2	1	-	1	1	1	3	4	3	5	6	5	1	1	C11	
Hypopharynx	299	0	-	-	-	-	-	-	-	6	8	26	54	64	48	49	43	C12-13	
Pharynx unspecified	142	0	-	-	-	-	-	-	-	1	11	8	31	25	20	22	24	C14	
Oesophagus	1178	0	-	-	-	2	1	1	9	9	41	98	173	224	204	220	196	C15	
Stomach	340	0	-	-	-	2	1	3	4	11	14	30	39	61	57	64	54	C16	
Small intestine	59	0	-	-	-	-	1	1	1	2	2	7	9	10	12	8	6	C17	
Colon	723	1	-	1	-	3	9	9	18	31	29	77	72	109	125	138	101	C18	
Rectum	841	0	-	-	-	2	2	9	10	41	47	70	111	118	158	135	138	C19-20	
Anus	78	0	-	-	-	-	-	1	1	2	4	5	7	15	14	10	19	C21	
Liver	432	1	4	-	-	4	-	4	2	6	12	16	47	78	108	89	61	C22	
Gallbladder etc.	102	0	-	-	-	2	1	-	-	5	2	10	15	17	14	20	16	C23-24	
Pancreas	94	0	-	-	-	1	-	1	-	3	6	9	10	24	18	11	11	C25	
Nose, sinuses etc.	87	0	-	1	-	-	-	1	6	2	6	12	12	12	14	15	6	C30-31	
Larynx	600	0	-	-	-	1	1	1	1	6	41	52	76	108	105	118	90	C32	
Trachea, bronchus and lung	1381	3	-	-	-	4	7	9	9	18	43	92	171	303	301	248	173	C33-34	
Other thoracic organs	68	0	-	2	3	2	3	9	2	7	5	7	11	6	2	5	4	C37-38	
Bone	131	0	3	10	22	24	12	3	7	6	3	2	4	11	8	7	6	C40-41	
Melanoma of skin	29	0	-	-	-	1	-	-	1	-	-	1	4	4	5	6	7	C43	
Other skin	271	0	-	-	-	-	4	6	4	12	10	26	29	42	28	45	65	C44	
Mesothelioma	8	0	-	-	-	-	2	-	-	-	-	-	-	4	1	1	-	C45	
Kaposi sarcoma	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	C46	
Connective and soft tissue	152	1	7	6	11	8	5	6	7	5	4	12	8	19	16	18	15	C47,C49	
Breast	188	0	-	-	-	1	-	3	9	14	16	25	20	23	29	25	23	C50	
Penis	87	0	1	-	-	-	-	-	3	4	2	6	10	15	19	15	12	C60	
Prostate	1226	2	-	-	1	-	1	1	-	3	3	30	57	150	241	338	399	C61	
Testis	85	0	1	1	6	6	16	12	5	8	5	4	5	7	3	2	3	C62	
Other male genital organs	16	0	1	1	-	-	-	-	-	-	-	2	3	5	1	1	2	C63	
Kidney	307	1	12	1	-	-	2	2	12	20	22	37	42	50	32	54	20	C64	
Renal pelvis	15	0	-	-	-	-	-	-	-	-	1	1	1	3	4	3	2	C65	
Ureter	6	0	-	-	-	-	-	-	-	-	-	1	-	3	1	1	-	C66	
Bladder	573	1	-	-	-	-	1	5	4	12	14	24	57	90	120	117	128	C67	
Other urinary organs	16	0	-	-	-	-	-	-	-	1	1	1	3	3	2	4	1	C68	
Eye	47	0	15	4	-	1	17	12	-	4	1	1	4	-	7	3	7	C69	
Brain, nervous system	310	0	8	16	13	12	17	12	12	23	21	33	31	37	28	23	5	C70-72	
Thyroid	560	0	-	5	11	31	30	51	48	83	65	41	40	63	37	37	18	C73	
Adrenal gland	27	0	10	2	-	2	1	-	-	1	1	-	3	2	3	2	-	C74	
Other endocrine	20	0	1	3	2	1	-	-	1	-	-	2	3	4	1	-	-	C75	
Hodgkin disease	150	1	1	5	11	13	12	11	12	8	8	9	9	14	7	17	11	C81	
Non-Hodgkin lymphoma	451	1	11	6	16	13	20	20	13	28	35	29	37	61	62	43	45	C82-85,C96	
Immunoproliferative diseases	8	0	-	-	-	-	-	-	-	-	-	2	2	-	1	3	-	C88	
Multiple myeloma	207	0	-	-	-	2	-	-	-	6	8	15	22	48	36	37	33	C90	
Lymphoid leukaemia	181	0	48	28	13	5	5	4	4	5	6	5	5	11	3	3	2	C91	
Myeloid leukaemia	245	0	16	3	6	11	10	2	14	18	21	19	15	23	19	32	18	C92-94	
Leukaemia unspecified	58	0	6	2	2	5	3	5	3	3	2	2	4	3	6	3	6	C95	
Myeloproliferative disorders	34	0	-	-	-	-	-	-	-	3	-	1	4	8	5	6	7	MPD	
Myelodysplastic syndromes	35	0	-	-	-	2	-	-	2	1	-	2	1	4	8	4	11	MDS	
Other and unspecified	942	1	4	1	6	2	8	11	15	14	34	51	85	93	161	148	146	OrU	
All sites	16398	17	151	102	117	129	156	175	247	302	598	819	1369	1950	2630	2669	2612	2355	ALL
All sites but C44	16127	17	151	102	117	129	156	171	241	298	586	809	1343	1921	2588	2641	2567	2290	ALLbC44

Table 12: Number of cancers by 5-year age group and ICD 10 site categories among females in Sri Lanka, 2022

Cancer Registry (2022)

Population-Sri Lanka 2022

Cases by age group (Period) - Female

SITE	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	41	-	-	1	-	1	-	-	-	-	-	4	1	7	5	9	13	0.2	C00
Tongue	235	-	-	-	-	1	-	4	5	11	17	21	25	43	34	36	38	1.2	C01-02
Mouth	516	-	-	-	-	2	2	1	8	11	18	43	55	85	88	107	95	2.7	C03-06
Salivary glands	95	-	-	1	2	5	1	3	6	8	10	11	8	15	5	10	9	0.5	C07-08
Tonsil	24	-	-	-	-	-	-	-	-	1	-	2	2	8	5	2	3	0.1	C09
Other oropharynx	19	-	-	-	-	-	-	-	-	1	-	2	3	1	4	4	4	0.1	C10
Nasopharynx	14	-	-	-	-	2	1	1	1	1	1	2	3	-	2	1	-	0.1	C11
Hypopharynx	56	-	-	-	-	-	1	1	3	2	2	10	5	6	11	4	12	0.3	C12-13
Pharynx unspecified	23	-	-	-	-	1	-	-	-	-	-	2	4	5	5	1	4	0.1	C14
Oesophagus	805	-	-	-	1	-	4	-	5	9	20	40	75	126	167	139	218	4.2	C15
Stomach	192	-	-	1	-	-	2	2	5	4	15	7	24	31	36	29	36	1.0	C16
Small intestine	49	-	-	-	-	-	2	3	2	1	3	6	7	6	7	6	6	0.3	C17
Colon	748	-	1	1	3	3	3	12	18	30	38	79	100	110	112	128	109	3.9	C18
Rectum	771	-	-	-	-	3	3	6	12	29	51	87	114	119	109	131	108	4.0	C19-20
Anus	55	-	-	-	-	-	-	-	3	1	1	7	5	9	8	7	14	0.3	C21
Liver	196	6	-	-	-	-	2	3	4	3	10	19	14	33	34	32	36	1.0	C22
Gallbladder etc.	119	0	-	-	-	1	-	3	5	5	3	9	19	23	26	8	18	0.6	C23-24
Pancreas	113	-	-	2	-	-	-	3	5	5	11	6	14	10	26	14	17	0.6	C25
Nose, sinuses etc.	60	-	-	-	1	1	-	1	3	2	4	4	7	11	11	8	7	0.3	C30-31
Larynx	63	-	-	-	-	1	-	1	2	3	2	1	8	10	7	15	13	0.3	C32
Trachea, bronchus and lung	553	-	-	1	1	7	4	4	10	20	38	63	58	80	86	100	81	2.9	C33-34
Other thoracic organs	58	1	1	-	2	-	1	3	4	3	4	9	1	7	7	8	7	0.3	C37-38
Bone	110	7	10	19	5	2	9	6	7	3	7	7	6	6	6	6	4	0.6	C40-41
Melanoma of skin	51	-	-	1	-	1	-	-	-	4	2	8	4	2	9	10	10	0.3	C43
Other skin	265	-	-	1	1	4	6	8	3	15	14	12	27	24	36	48	65	1.4	C44
Mesothelioma	4	-	-	-	-	-	-	-	-	-	-	-	-	4	-	-	-	0.0	C45
Kaposi sarcoma	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	C46
Connective and soft tissue	128	0	9	6	2	-	5	10	10	8	8	11	15	13	11	7	10	0.7	C47,C49
Breast	5447	1	-	-	-	11	37	85	233	499	667	701	781	769	653	564	446	28.4	C50
Vulva	51	-	-	-	-	-	-	1	1	-	6	3	6	5	6	11	12	0.3	C51
Vagina	70	-	-	-	-	-	-	1	1	1	1	1	6	11	15	13	21	0.4	C52
Cervix uteri	1226	1	-	-	-	-	1	11	47	80	105	145	178	201	158	150	148	6.4	C53
Corpus uteri	976	-	-	-	1	4	7	11	14	32	50	101	130	210	195	135	86	5.1	C54
Uterus unspecified	262	0	-	-	3	3	7	3	9	11	21	20	39	42	40	46	21	1.4	C55
Ovary	1112	0	3	13	17	22	25	19	42	66	104	133	151	169	160	98	87	5.8	C56
Other female genital organs	48	-	-	1	-	2	-	1	2	5	4	4	8	13	6	1	1	0.3	C57
Placenta	7	0	-	-	-	1	3	1	1	1	1	-	-	-	-	-	-	0.0	C58
Kidney	130	0	9	-	1	-	-	2	2	6	12	13	7	20	22	20	12	0.7	C64
Renal pelvis	12	0	-	-	2	-	-	1	-	2	1	-	1	1	2	2	-	0.1	C65
Ureter	14	0	-	-	-	1	-	-	-	-	1	1	-	3	4	3	1	0.1	C66
Bladder	161	0	-	-	1	-	2	1	7	4	5	8	18	21	28	27	39	0.8	C67
Other urinary organs	5	0	-	-	-	-	-	-	-	-	-	-	2	-	2	-	1	0.0	C68
Eye	24	0	-	-	-	2	-	2	-	1	2	2	2	1	1	1	1	0.1	C69
Brain, nervous system	251	0	15	10	11	5	9	10	15	23	19	28	23	23	16	13	10	1.3	C70-72
Thyroid	2369	1	5	6	57	97	192	209	312	356	319	250	186	149	105	72	52	12.3	C73
Adrenal gland	19	0	4	1	-	1	-	-	1	1	-	3	2	1	2	4	-	0.1	C74
Other endocrine	20	0	-	-	2	2	-	-	1	4	1	-	1	4	-	1	1	0.1	C75
Hodgkin disease	103	0	-	1	7	10	10	9	4	5	8	5	8	16	12	5	3	0.5	C81
Non-Hodgkin lymphoma	325	0	1	9	6	9	9	13	16	23	19	30	29	46	42	29	40	1.7	C82-85,C96
Immunoproliferative diseases	6	0	-	-	-	1	-	-	-	-	1	-	-	1	1	1	1	0.0	C88
Multiple myeloma	202	0	-	-	-	-	-	-	1	1	11	15	23	44	47	35	24	1.1	C90
Lymphoid leukaemia	135	0	39	20	18	8	1	2	3	3	3	8	7	9	6	4	3	0.7	C91
Myeloid leukaemia	212	0	9	6	4	5	4	11	10	11	9	14	23	26	24	28	24	1.1	C92-94
Leukaemia unspecified	48	0	4	3	1	1	1	-	4	7	6	5	4	5	3	3	1	0.3	C95
Myeloproliferative disorders	19	0	-	-	-	-	-	-	1	1	2	-	2	2	6	4	1	0.1	MPD
Myelodysplastic syndromes	37	0	-	-	-	-	-	-	-	1	2	5	-	10	9	4	6	0.2	MDS
Other and unspecified	803	1	-	1	4	3	6	7	16	22	38	52	97	85	121	119	106	4.2	O&U
All sites	19457	11	117	82	103	139	218	358	483	868	1362	1714	2064	2326	2717	2541	2104	100.0	ALL
All sites but C44	19192	10	117	82	102	138	214	352	475	865	1347	1700	2052	2693	2505	2202	2039		ALLbC44

Table built Mon Sep 15 10:05:39 IST 2025 by CanReg5.

Table 13: Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by 5-year age group and ICD 10 site categories among males in Sri Lanka, 2022

Cancer Registry (2022)

Population-Sri Lanka 2022

Incidence per 100,000 by age group (Period) - Male

SITE	ALL AGES	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 65-74	ASR (10th)	ICD
Lip	123	-	0.1	-	-	-	-	0.1	0.3	0.3	0.7	1.4	4.8	4.5	3.9	12.2	8.2	1.1	0.8	0.06	0.14	1.1	C00
Tongue	1025	-	-	-	-	0.1	0.4	1.5	3.2	6.9	11.1	23.5	31.7	61.4	51.9	51.2	39.8	38.7	6.4	0.59	1.10	8.8	C01-02
Mouth	1865	0.1	0.2	-	0.1	0.4	0.7	0.8	3.5	10.0	20.2	33.5	52.1	104.5	129.7	102.6	17.4	17.4	11.6	0.92	2.09	16.2	C03-06
Salivary glands	140	0.1	-	0.1	0.2	0.2	0.1	0.3	0.8	1.7	1.3	1.9	3.7	5.2	6.2	8.6	4.5	1.3	0.9	0.08	0.15	1.2	C07-08
Tonsil	194	-	-	-	-	-	-	-	0.3	0.7	1.2	2.8	8.4	7.6	10.1	11.7	10.3	1.8	1.2	0.11	0.21	1.7	C09
Other oropharynx	208	-	-	-	-	-	-	0.2	-	0.4	1.6	4.6	7.7	8.4	12.7	13.2	7.0	1.9	1.3	0.12	0.24	1.8	C10
Nasopharynx	34	-	-	0.2	0.1	-	-	0.1	0.1	0.4	0.6	0.5	0.9	1.3	1.6	0.5	0.4	0.3	0.2	0.02	0.03	0.3	C11
Hypopharynx	299	-	-	-	-	-	-	-	0.1	0.8	1.2	4.1	9.9	13.8	15.6	24.8	17.7	2.8	1.9	0.15	0.35	2.6	C12-13
Pharynx unspecified	142	-	-	-	-	-	-	-	-	0.1	1.6	1.3	5.7	5.4	6.5	11.1	9.9	1.3	0.9	0.07	0.16	1.2	C14
Oesophagus	1178	-	-	-	-	0.2	0.1	0.1	1.2	1.2	6.1	15.5	31.7	48.4	66.2	111.4	80.5	11.0	7.3	0.52	1.41	10.4	C15
Stomach	340	-	-	-	-	0.2	0.1	0.3	0.5	1.5	2.1	4.7	7.2	13.2	18.5	32.4	22.2	3.2	2.1	0.15	0.40	3.0	C16
Small intestine	59	-	-	-	-	0.1	0.1	0.1	0.1	0.3	0.3	1.1	1.7	2.2	3.9	4.1	2.5	0.5	0.4	0.03	0.07	0.5	C17
Colon	723	-	-	0.1	-	0.4	1.1	1.0	2.4	4.3	4.3	12.2	13.2	23.6	40.6	69.9	41.5	6.7	4.5	0.31	0.87	6.4	C18
Rectum	841	-	-	-	-	0.2	0.2	1.0	1.3	5.7	7.0	11.1	20.4	25.5	51.3	68.4	56.6	7.8	5.2	0.36	0.96	7.4	C19-20
Anus	78	-	-	-	-	-	-	0.1	0.1	0.3	0.6	0.8	1.3	3.2	4.5	5.1	7.8	0.7	0.5	0.03	0.08	0.7	C21
Liver	432	0.4	-	-	-	0.5	-	0.5	0.3	0.8	1.8	2.5	8.6	16.9	35.1	45.1	25.0	4.0	2.7	0.16	0.56	3.9	C22
Gallbladder etc.	102	-	-	-	-	0.2	0.1	-	-	0.7	0.3	1.6	2.8	3.7	4.5	10.1	6.6	0.9	0.6	0.05	0.12	0.9	C23-24
Pancreas	94	-	-	-	-	0.1	-	0.1	-	0.4	0.9	1.4	1.8	5.2	5.8	5.6	4.5	0.9	0.6	0.05	0.11	0.8	C25
Nose, sinuses etc.	87	-	-	0.1	-	-	-	0.1	0.8	0.3	0.9	1.9	2.2	2.6	4.5	7.6	2.5	0.8	0.5	0.04	0.11	0.8	C30-31
Larynx	600	-	-	-	-	0.1	0.1	0.1	0.1	0.8	6.1	8.2	13.9	23.3	34.1	59.8	36.9	5.6	3.7	0.26	0.73	5.3	C32
Trachea, bronchus and lung	1381	-	-	-	-	0.5	0.9	1.0	1.2	2.5	6.4	14.5	31.4	65.5	97.7	125.6	71.0	12.9	8.6	0.62	1.74	12.3	C33-34
Other thoracic organs	68	-	-	0.2	0.3	0.2	0.4	1.0	0.3	1.0	0.7	1.1	2.0	1.3	0.6	2.5	1.6	0.6	0.4	0.04	0.06	0.6	C37-38
Bone	131	0.3	1.0	2.4	2.7	1.5	0.4	0.3	0.9	0.8	0.4	0.3	0.7	2.4	2.6	3.5	2.5	1.2	0.8	0.07	0.10	1.2	C40-41
Melanoma of skin	29	-	-	-	-	0.1	-	-	0.1	-	-	0.2	0.7	0.9	1.6	3.0	2.9	0.3	0.2	0.01	0.03	0.3	C43
Other skin	271	-	-	-	-	0.1	-	0.5	0.7	1.5	1.5	4.1	5.3	9.1	9.1	22.8	26.7	2.5	1.7	0.12	0.28	2.3	C44
Mesothelioma	8	-	-	-	-	-	0.2	-	-	-	-	-	-	-	0.9	0.3	0.5	0.1	0.0	0.01	0.01	0.1	C45
Kaposi sarcoma	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.00	0.00	0.0	C46
Connective and soft tissue	152	1	0.7	1.2	0.9	0.6	0.7	0.8	0.7	0.6	0.6	1.9	1.5	4.1	5.2	9.1	6.2	1.4	0.9	0.08	0.15	1.4	C47,C49
Breast	188	-	-	-	-	0.1	-	0.3	1.2	1.9	2.4	4.0	3.7	5.0	9.4	12.7	9.4	1.8	1.2	0.09	0.20	1.6	C50
Penis	87	0.1	-	-	-	-	-	-	0.4	0.6	0.3	0.9	1.8	3.2	6.2	7.6	4.9	0.8	0.5	0.04	0.11	0.8	C60
Prostate	1226	2	-	-	0.1	-	0.1	0.1	-	0.4	0.4	4.7	10.5	32.4	78.2	171.2	163.8	11.4	7.6	0.24	1.49	11.1	C61
Testis	85	0	0.1	0.1	0.7	0.7	2.0	1.4	0.7	1.1	0.7	0.6	0.9	1.5	1.0	1.0	1.2	0.8	0.5	0.05	0.06	0.7	C62
Other male genital organs	16	0.1	0.1	-	-	-	-	-	-	-	-	0.3	0.6	1.1	0.3	0.5	0.8	0.1	0.1	0.01	0.01	0.1	C63
Kidney	307	1	1.2	0.1	-	-	0.2	0.2	1.6	2.8	3.3	5.8	7.7	10.8	10.4	27.4	8.2	2.9	1.9	0.17	0.36	2.7	C64
Renal pelvis	15	0	-	-	-	-	-	-	-	-	0.1	0.2	0.2	0.6	1.3	1.5	0.8	0.1	0.1	0.01	0.02	0.1	C65
Ureter	6	-	-	-	-	-	-	-	-	-	-	0.2	-	0.6	0.3	0.5	-	0.1	0.0	0.00	0.01	0.1	C66
Bladder	573	-	-	-	-	-	0.1	0.6	0.5	1.7	2.1	3.8	10.5	19.5	38.9	59.3	52.5	5.3	3.6	0.19	0.69	5.1	C67
Other urinary organs	16	-	-	-	-	-	-	-	-	0.1	0.1	0.2	0.6	0.6	0.6	2.0	0.4	0.1	0.1	0.01	0.02	0.1	C68
Eye	47	0	0.4	-	-	0.1	-	-	-	0.6	0.1	0.2	0.7	-	2.3	1.5	2.9	0.4	0.3	0.02	0.04	0.5	C69
Brain, nervous system	310	0	0.8	1.8	1.5	1.5	2.1	1.4	1.6	3.2	3.1	5.2	5.7	8.0	9.1	11.7	2.1	2.9	1.9	0.19	0.29	2.8	C70-72
Thyroid	560	0	-	0.6	1.2	3.8	3.7	5.9	6.4	11.5	9.7	6.5	7.3	13.6	12.0	18.7	7.4	5.2	3.5	0.35	0.50	4.8	C73
Adrenal gland	27	0	1.0	0.2	-	0.2	0.1	-	-	0.1	0.1	-	0.6	0.4	1.0	1.0	-	0.3	0.2	0.01	0.02	0.3	C74
Other endocrine	20	0	0.1	0.3	0.2	0.1	0.2	-	0.1	-	-	0.3	0.6	0.9	0.3	-	-	0.2	0.1	0.01	0.02	0.2	C75
Hodgkin disease	150	1	0.1	0.6	1.2	1.6	1.5	1.3	1.6	1.1	1.2	1.4	1.7	3.0	2.3	8.6	4.5	1.4	0.9	0.08	0.14	1.3	C81
Non-Hodgkin lymphoma	451	1	1.1	0.7	1.8	1.6	2.5	2.3	1.7	3.9	5.2	4.6	6.8	13.2	20.1	21.8	18.5	4.2	2.8	0.23	0.44	4.0	C82-85,C96
Immunoproliferative diseases	8	-	-	-	-	-	-	-	-	-	-	0.3	0.4	-	0.3	1.5	-	0.1	0.0	0.00	0.01	0.1	C88
Multiple myeloma	207	0	-	-	-	0.2	-	-	-	0.8	1.2	2.4	4.0	10.4	11.7	18.7	13.5	1.9	1.3	0.10	0.25	1.8	C90
Lymphoid leukaemia	181	0	5.0	3.5	3.1	1.5	0.6	0.5	0.5	0.7	0.9	0.8	0.9	2.4	1.0	1.5	0.8	1.7	1.1	0.10	0.12	1.9	C91
Myeloid leukaemia	245	0	1.7	0.3	0.7	1.2	1.2	1.6	2.4	2.5	3.1	3.0	2.8	5.0	6.2	16.2	7.4	2.3	1.5	0.13	0.24	2.2	C92-94
Leukaemia unspecified	58	0	0.6	0.2	0.2	0.6	0.4	0.6	0.4	0.4	0.3	0.3	0.7	0.6	1.9	1.5	2.5	0.5	0.4	0.03	0.05	0.5	C95
Myeloproliferative disorders	34	0	-	-	-	-	-	-	-	0.4	-	0.2	0.7	1.7	1.6	3.0	2.9	0.3	0.2	0.02	0.04	0.3	MPD
Myelodysplastic syndromes	35	0	-	-	-	-	-	-	-	0.3	0.1	-	0.3	0.2	0.9	2.6	2.0	0.3	0.2	0.01	0.03	0.3	MDS
Other and unspecified	942	1	0.4	0.1	0.7	0.2	1.0	1.4	1.7	1.9	4.7	7.6	13.4	17.1	34.8	48.0	59.9	8.8	5.8	0.43	1.08	8.3	O&U
All sites	16398	17	15.7	10.6	12.9	14.4	19.3	21.6	28.5	40.4	83.0	121.7	216.3	357.8	568.5	866.2	966.7	152.7	7.56	18.52	144.9	ALL	
All sites but C44	16127	17	15.7	10.6	12.9	14.4	19.3	21.1	27.8	39.9	81.4	120.2	212.2	352.4	559.5	857.1	940.0	150.2	100.0	7.45	18.24	142.6	ALLbC44

, Reference population: World Standard Population

Table built Mon Sep 15 10:06:17 IST 2025 by CanReg5.

Table 14: Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by 5-year age group and ICD 10 site categories among females in Sri Lanka

Cancer Registry (2022)

Population-Sri Lanka 2022

Incidence per 100,000 by age group (Period) - Female

S I T E	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 64-74	ASR	ICD (10th)
Lip	41	-	-	0.1	-	0.1	-	-	-	-	-	0.6	0.2	1.3	1.3	3.6	3.6	0.4	0.2	0.01	0.04	0.3	C00
Tongue	235	-	-	-	-	0.1	-	0.4	0.6	1.4	2.3	3.0	4.1	8.0	9.0	14.4	10.6	2.1	1.2	0.10	0.22	1.7	C01-02
Mouth	516	-	-	-	-	0.2	0.2	0.1	1.0	1.4	2.5	6.2	9.0	15.9	23.2	42.8	26.4	4.5	2.7	0.18	0.51	3.7	C03-06
Salivary glands	95	-	-	0.1	0.2	0.6	0.1	0.3	0.8	1.1	1.4	1.6	1.3	2.8	1.3	4.0	2.5	0.8	0.5	0.05	0.08	0.7	C07-08
Tonsil	24	-	-	-	-	-	-	-	0.1	0.1	-	0.3	0.3	1.5	1.3	0.8	0.8	0.2	0.1	0.01	0.02	0.2	C09
Other oropharynx	19	-	-	-	-	-	-	-	-	0.1	-	0.3	0.5	0.2	1.1	1.6	1.1	0.2	0.1	0.01	0.02	0.1	C10
Nasopharynx	14	-	-	-	-	0.2	0.1	-	0.1	0.1	-	0.3	0.5	-	0.5	0.4	-	0.1	0.1	0.01	0.01	0.1	C11
Hypopharynx	56	-	-	-	-	-	-	0.1	0.4	0.3	0.3	1.4	0.8	1.1	2.9	1.6	3.3	0.5	0.3	0.02	0.04	0.4	C12-13
Pharynx unspecified	23	-	-	-	-	0.1	-	-	-	-	0.1	0.3	0.7	0.9	1.3	0.4	1.1	0.2	0.1	0.01	0.02	0.2	C14
Oesophagus	805	-	-	-	0.1	-	0.5	-	0.6	1.2	2.8	5.8	12.2	23.5	44.0	55.6	60.6	7.0	4.2	0.23	0.73	5.7	C15
Stomach	192	-	-	0.1	-	-	0.2	0.2	0.6	0.5	2.1	1.0	3.9	5.8	9.5	11.6	10.0	1.7	1.0	0.07	0.18	1.4	C16
Small intestine	49	-	-	-	-	-	0.2	0.3	0.1	0.4	0.9	1.1	1.1	1.1	1.8	2.4	1.7	0.4	0.3	0.02	0.04	0.4	C17
Colon	748	-	0.1	0.1	0.3	0.3	0.3	1.3	2.3	4.0	5.2	11.4	16.3	20.6	29.5	51.2	30.3	6.5	3.9	0.31	0.72	5.4	C18
Rectum	771	-	-	-	-	0.3	0.1	0.7	1.5	3.8	7.0	12.5	18.6	22.2	28.7	52.4	30.0	6.7	4.0	0.33	0.74	5.6	C19-20
Anus	55	-	-	-	-	-	-	-	0.1	0.1	0.4	1.0	0.8	1.7	2.1	2.8	3.9	0.5	0.3	0.02	0.05	0.4	C21
Liver	196	0.6	-	-	-	-	0.2	0.3	0.5	0.4	1.4	2.7	2.3	6.2	9.0	12.8	10.0	1.7	1.0	0.07	0.18	1.5	C22
Gallbladder etc.	119	0	-	-	-	0.1	-	0.3	0.5	0.7	0.4	1.3	3.1	4.3	6.9	3.2	5.0	1.0	0.6	0.05	0.10	0.9	C23-24
Pancreas	113	-	-	0.2	-	-	-	0.3	0.6	0.7	1.5	0.9	2.3	1.9	6.9	5.6	4.7	1.0	0.6	0.04	0.10	0.8	C25
Nose, sinuses etc.	60	-	-	-	0.1	0.1	-	0.1	0.4	0.3	0.6	0.6	1.1	2.1	2.9	3.2	1.9	0.5	0.3	0.03	0.06	0.4	C30-31
Larynx	63	-	-	-	-	0.1	-	0.1	0.3	0.4	0.3	0.1	1.3	1.9	1.8	6.0	3.6	0.6	0.3	0.02	0.06	0.5	C32
Trachea, bronchus and lung	553	-	-	0.1	0.1	0.8	0.5	0.4	1.3	2.6	5.2	9.1	9.5	15.0	22.7	40.0	22.5	4.8	2.9	0.22	0.54	4.1	C33-34
Other thoracic organs	58	0.1	0.1	-	0.2	-	0.1	0.3	0.5	0.4	0.6	1.3	0.2	1.3	1.8	3.2	1.9	0.5	0.3	0.03	0.05	0.4	C37-38
Bone	110	0.7	1.1	2.1	0.6	0.2	1.0	0.7	0.9	0.4	1.0	1.0	1.0	1.1	1.6	2.4	1.1	1.0	0.6	0.06	0.08	1.0	C40-41
Melanoma of skin	51	-	-	0.1	-	0.1	-	0.5	0.3	0.4	0.3	0.1	1.3	0.4	2.4	4.0	2.8	0.4	0.3	0.02	0.05	0.4	C43
Other skin	265	-	-	0.1	0.1	0.5	0.7	0.9	0.4	2.0	1.9	1.7	4.4	4.5	9.5	19.2	18.1	2.3	1.4	0.09	0.23	1.9	C44
Mesothelioma	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.00	0.00	0.0	C45
Kaposi sarcoma	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.00	0.00	0.0	C46
Connective and soft tissue	128	1.0	0.3	0.7	0.2	-	0.6	1.1	1.3	1.1	1.1	1.6	2.4	2.4	2.9	2.8	2.8	1.1	0.7	0.00	0.10	1.0	C47,C49
Breast	5447	-	-	-	-	1.3	4.2	9.3	29.6	65.7	91.8	101.0	127.5	143.7	172.2	225.6	124.0	47.6	28.4	2.87	4.86	40.3	C50
Vulva	51	-	-	-	-	-	-	0.1	0.1	-	0.8	0.4	1.0	0.9	1.6	4.4	3.3	0.4	0.3	0.02	0.05	0.4	C51
Vagina	70	-	-	-	-	-	-	-	0.1	0.1	0.1	0.1	1.0	2.1	4.0	5.2	5.8	0.6	0.4	0.02	0.06	0.5	C52
Cervix uteri	1226	-	-	-	0.1	-	0.1	1.2	6.0	10.5	14.4	20.9	29.1	37.6	41.7	60.0	41.1	10.7	6.4	0.60	1.11	8.9	C53
Corpus uteri	976	-	-	-	-	0.5	0.8	1.2	1.8	4.2	9.9	14.5	21.2	39.2	51.4	54.0	23.9	8.5	5.1	0.45	0.98	7.2	C54
Uterus unspecified	262	-	-	-	-	0.3	0.8	0.3	1.1	1.4	2.9	2.9	6.4	7.8	10.5	18.4	5.8	2.3	1.4	0.12	0.26	2.0	C55
Ovary	1112	0.3	0.3	1.5	1.9	2.6	2.8	2.1	5.3	8.7	14.3	19.2	24.6	31.6	42.2	39.2	24.2	9.7	5.8	0.58	0.98	8.4	C56
Other female genital organs	48	-	-	0.1	-	0.2	-	0.1	0.3	0.7	0.6	0.6	1.3	2.4	1.6	0.4	0.3	0.4	0.3	0.03	0.04	0.4	C57
Placenta	7	-	-	-	0.1	-	0.3	0.1	-	0.1	0.1	-	-	-	-	-	-	0.1	0.0	0.00	0.00	0.1	C58
Kidney	130	1.0	0.4	-	0.1	-	-	0.2	0.3	0.8	1.7	1.9	1.1	3.7	5.8	8.0	3.3	1.1	0.7	0.06	0.12	1.0	C64
Renal pelvis	12	-	-	-	0.2	-	-	0.1	-	0.3	0.1	-	0.2	0.2	0.5	0.8	-	0.1	0.1	0.01	0.01	0.1	C65
Ureter	14	-	-	-	-	0.1	-	-	-	-	0.1	0.1	-	0.6	1.1	1.2	0.3	0.1	0.1	0.00	0.02	0.1	C66
Bladder	161	-	-	-	0.1	-	0.2	0.1	0.9	0.5	0.7	1.2	2.9	3.9	7.4	10.8	10.8	1.4	0.8	0.05	0.14	1.1	C67
Other urinary organs	5	-	-	-	-	-	-	-	-	-	-	-	0.3	-	0.5	-	0.3	0.0	0.0	0.00	0.00	0.0	C68
Eye	24	1.0	-	-	-	0.2	-	0.2	-	0.1	0.3	0.3	0.3	0.2	0.3	0.4	0.3	0.2	0.1	0.01	0.02	0.2	C69
Brain, nervous system	251	0	2.2	1.1	1.2	0.6	1.0	1.1	1.9	3.0	2.6	4.0	3.8	4.3	4.2	5.2	2.8	2.2	1.3	0.14	0.19	2.1	C70-72
Thyroid	2369	1	0.1	0.5	0.7	6.3	11.3	22.8	39.6	46.9	43.9	36.0	30.4	27.8	27.7	28.8	14.5	20.7	12.3	1.44	1.72	18.4	C73
Adrenal gland	19	0.4	-	0.1	-	0.1	-	-	-	0.1	-	0.4	0.3	0.2	0.5	1.6	-	0.2	0.1	0.01	0.02	0.2	C74
Other endocrine	20	0	-	-	0.2	0.1	-	-	0.1	0.5	0.1	-	0.2	0.7	-	0.4	0.3	0.2	0.1	0.01	0.01	0.2	C75
Hodgkin disease	103	-	-	0.1	0.8	1.2	1.1	1.0	0.5	0.7	1.1	0.7	1.3	3.0	3.2	2.0	0.8	0.9	0.5	0.06	0.08	0.8	C81
Non-Hodgkin lymphoma	325	0	0.4	1.0	0.7	1.0	1.0	1.4	2.0	3.0	2.6	4.3	4.7	8.6	11.1	11.6	11.1	2.8	1.7	0.16	0.27	2.5	C82-85,C96
Immunoproliferative diseases	6	-	-	-	-	0.1	-	-	-	-	-	-	-	0.2	0.3	0.4	0.3	0.1	0.0	0.00	0.01	0.0	C88
Multiple myeloma	202	0	-	0.1	-	-	-	-	0.1	0.1	1.5	2.2	3.8	8.2	12.4	14.0	6.7	1.8	1.1	0.08	0.21	1.5	C90
Lymphoid leukaemia	135	0	4.1	2.1	0.9	0.1	0.1	0.2	0.4	0.4	0.4	1.2	1.1	1.7	1.6	1.6	0.8	1.2	0.7	0.07	0.09	1.3	C91
Myeloid leukaemia	212	0	1.0	0.6	0.5	0.4	0.5	1.2	1.3	1.4	1.2	2.0	3.8	4.9	6.3	11.2	6.7	1.9	1.1	0.10	0.18	1.6	C92-94
Leukaemia unspecified	48	0	0.4	0.3	0.1	-	0.1	-	0.5	0.9	0.8	0.7	0.7	0.9	0.8	1.2	0.3	0.4	0.3	0.03	0.04	0.4	C95
Myeloproliferative disorders	19	0	-	-	-	-	-	-	0.1	0.1	0.3	-	0.3	0.4	1.6	1.6	0.3	0.2	0.1	0.01	0.02	0.1	MPD
Myelodysplastic syndromes	37	0	-	-	-	-	-	-	-	0.1	0.3	0.7	-	1.9	2.4	1.6	1.7	0.3	0.2	0.01	0.03	0.3	MDS
Other and unspecified	803	1	-	0.1	0.5	0.3	0.7	0.8	1.7	2.8	5.0	7.2	14.0	22.6	31.4	42.4	34.7	7.0	4.2	0.35	0.72	5.9	OKU
All sites	19457	11	12.4	8.7	11.6	15.5	25.3	40.6	52.6	110.2	179.4	235.9	297.3	379.6	670.1	900.1	584.8	170.1	100.0	9.39	17.02	145.0	ALL
All sites but C44	19192	10	12.4	8.7	11.5	15.3	24.8	39.9	51.7	109.9	177.4	234.0	295.6	375.2	603.3	880.9	566.7	167.7	100.0	9.30	17.02	143.1	ALLbC44

, Reference population: World Standard Population

Table builtMon Sep 15 10:06:17 IST 2025 by CanReg5.

Table 15: Lip, tongue and mouth cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	3013	18.8	26.1	3.3
Female	792	4.1	5.7	0.8

ASR – Age Standardized Incidence Rate per 100, 000 population

Cum. Rate (0-74 years) per 100, 000 population

ICD 10 code and site	Male	Female
C00.0 External upper lip	7	2
C00.1 External lower lip	27	8
C00.2 External lip, NOS	2	2
C00.3 Mucosa of upper lip	10	0
C00.4 Mucosa of lower lip	20	9
C00.5 Mucosa of lip, NOS	5	2
C00.6 Commissure of lip	29	8
C00.8 Overl. lesion of lip	4	3
C00.9 Lip, NOS	19	7
C01.9 Base of tongue, NOS	245	55
C02.0 Dorsal surface of tongue, NOS	21	5
C02.1 Border of tongue	238	77
C02.2 Ventral surface of tongue, NOS	25	2
C02.3 Anterior 2/3 of tongue, NOS	13	4
C02.4 Lingual tonsil	4	1
C02.8 Overl. lesion of tongue	16	3
C02.9 Tongue, NOS	463	88
C03.0 Upper gum	17	7
C03.1 Lower gum	61	21
C03.9 Gum, NOS	32	17
C04.0 Anterior floor of mouth	21	5
C04.1 Lateral floor of mouth	15	4
C04.8 Overl. lesion of floor of mouth	7	2
C04.9 Floor of mouth, NOS	163	29
C05.0 Hard palate	51	29
C05.1 Soft palate, NOS	125	15
C05.2 Uvula	17	0
C05.8 Overl. lesion of palate	7	2
C05.9 Palate, NOS	91	27
C06.0 Cheek mucosa	816	250
C06.1 Vestibule of mouth	35	13
C06.2 Retromolar area	117	23
C06.8 Overl. lesion of other/unspec. parts of mouth	18	4
C06.9 Mouth, NOS	272	68
Total	3013	792

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	163	53
8001 Tumor cells, malignant	6	1
8010 Carcinoma, NOS	172	47
8011 Epithelioma, malignant	1	0
8020 Carcinoma, undifferentiated, NOS	0	1
8032 Spindle cell carcinoma, NOS	23	12
8033 Pseudosarcomatous carcinoma	3	0
8034 Polygonal cell carcinoma	1	0
8050 Papillary carcinoma, NOS	2	2
8051 Verrucous carcinoma, NOS	56	17
8052 Papillary squamous cell carcinoma	5	2
8070 Squamous cell carcinoma, NOS	2469	603
8071 Squamous cell carcinoma, keratinizing, NOS	22	7
8072 Squamous cell carcinoma, large cell, nonkeratinizing	2	1
8074 Squamous cell carcinoma, spindle cell	3	2
8076 Squamous cell carcinoma, microinvasive	20	2
8082 Lymphoepithelial carcinoma	0	1
8083 Basaloid squamous cell carcinoma	12	0
8140 Adenocarcinoma, NOS	22	14
8200 Adenoid cystic carcinoma	7	7
8230 Solid carcinoma, NOS	1	0
8246 Neuroendocrine carcinoma, NOS	1	0
8260 Papillary adenocarcinoma, NOS	1	0
8310 Clear cell adenocarcinoma, NOS	1	0
8320 Granular cell carcinoma	0	1
8430 Mucoepidermoid carcinoma	8	9
8480 Mucinous adenocarcinoma	0	4
8500 Infiltrating duct carcinoma, NOS	1	1
8560 Adenosquamous carcinoma	0	1
8562 Epithelial-myoepithelial carcinoma	1	0
8723 Malignant melanoma, regressing	1	1
8730 Amelanotic melanoma	1	0
8800 Sarcoma, NOS	2	0
8810 Fibrosarcoma, NOS	0	1
8895 Myosarcoma	1	0
8900 Rhabdomyosarcoma, NOS	1	0
8910 Embryonal rhabdomyosarcoma, NOS	2	0
8941 Carcinoma in pleomorphic adenoma	1	0
9150 Hemangiopericytoma, malignant	1	0
9170 Lymphangiosarcoma	0	1
9580 Granular cell tumor, malignant	0	1
Total	3013	792




Figure 21: Age Specific Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2022




Figure 22: Age Standardized Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2005-2022

Table 16: Pharyngeal cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	877	5.5	7.6	1.0
Female	136	0.7	1.0	0.1

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C09.0 Tonsillar fossa	22	2
C09.1 Tonsillar pillar	5	0
C09.8 Overl. lesion of tonsil	0	1
C09.9 Tonsil, NOS	167	20
C10.0 Vallecula	101	3
C10.1 Anterior surface of epiglottis	25	3
C10.2 Lateral wall of oropharynx	3	0
C10.3 Posterior wall of oropharynx	13	3
C10.4 Branchial cleft	1	0
C10.9 Oropharynx, NOS	65	10
C11.1 Posterior wall of nasopharynx	4	1
C11.2 Lateral wall of nasopharynx	1	0
C11.3 Anterior wall of nasopharynx	1	0
C11.8 Overl. lesion of nasopharynx	0	1
C11.9 Nasopharynx, NOS	28	12
C12.9 Pyriform sinus	199	21
C13.0 Postcricoid region	27	20
C13.1 Aryepiglottic fold	31	3
C13.2 Posterior wall of hypopharynx	2	4
C13.8 Overl. lesion of hypopharynx	1	0
C13.9 Laryngopharynx, Hypopharynx NOS	39	8
C14.0 Pharynx, NOS	115	19
C14.8 Overl. lesion of lip, oral cavity, pharynx	27	5
Total	877	136

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	73	14
8004	Malignant tumor, spindle cell type	1	0
8010	Carcinoma, NOS	67	15
8011	Epithelioma, malignant	1	0
8020	Carcinoma, undifferentiated, NOS	1	1
8032	Spindle cell carcinoma, NOS	13	4
8050	Papillary carcinoma, NOS	1	0
8070	Squamous cell carcinoma, NOS	686	93
8071	Squamous cell carcinoma, keratinizing, NOS	7	2
8072	Squamous cell carcinoma, large cell, nonkeratinizing	2	0
8082	Lymphoepithelial carcinoma	5	0
8083	Basaloid squamous cell carcinoma	8	1
8140	Adenocarcinoma, NOS	9	3
8141	Scirrhous adenocarcinoma	0	1
8200	Adenoid cystic carcinoma	0	1
8260	Papillary adenocarcinoma, NOS	1	0
8550	Acinar cell carcinoma	0	1
8720	Malignant melanoma, NOS (except juvenile melanoma)	1	0
8800	Sarcoma, NOS	1	0
Total		877	136




Figure 23: Age Specific Incidence Rates of Pharyngeal cancer in Sri Lanka, 2022




Figure 24: Age Standardized Incidence Rates of Pharyngeal cancer in Sri Lanka, 2012-2022

Table 17: Oesophageal cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	1178	7.3	10.4	1.4
Female	805	4.2	5.7	0.7

ASR – Age Standardized Incidence Rate per 100, 000 population
Cum. Rate (0-74 years) per 100, 000 population

ICD 10 code and site	Male	Female
C15.0 Cervical esophagus	18	5
C15.1 Thoracic esophagus	5	2
C15.2 Abdominal esophagus	19	7
C15.3 Upper third of esophagus	14	19
C15.4 Middle third of esophagus	67	56
C15.5 Lower third of esophagus	128	57
C15.8 Overl. lesion of esophagus	6	1
C15.9 Oesophagus, NOS	921	658
Total	1178	805

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	65	44
8002 Malignant tumor, small cell type	0	1
8005 Malignant tumor, clear cell type	1	0
8010 Carcinoma, NOS	102	70
8032 Spindle cell carcinoma, NOS	10	9
8041 Small cell carcinoma, NOS	2	0
8050 Papillary carcinoma, NOS	2	0
8070 Squamous cell carcinoma, NOS	726	597
8071 Squamous cell carcinoma, keratinizing, NOS	7	4
8072 Squamous cell carcinoma, large cell, nonkeratinizing	0	1
8076 Squamous cell carcinoma, microinvasive	2	2
8083 Basaloid squamous cell carcinoma	7	4
8140 Adenocarcinoma, NOS	235	64
8144 Adenocarcinoma, intestinal type	3	1
8211 Tubular adenocarcinoma	0	1
8246 Neuroendocrine carcinoma, NOS	5	3
8480 Mucinous adenocarcinoma	1	1
8490 Signet ring cell carcinoma	9	2
8560 Adenosquamous carcinoma	1	1
Total	1178	805




Figure 25: Age Specific Incidence Rates of Oesophageal cancer in Sri Lanka, 2022




Figure 26: Age Standardized Incidence Rates of Oesophageal cancer in Sri Lanka, 2005-2022

Table 18: Stomach cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	340	2.1	3.0	0.4
Female	192	1.0	1.4	0.2

ASR – Age Standardized Incidence Rate per 100, 000 population
Cum. Rate (0-74 years) per 100, 000 population

ICD 10 code and site	Male	Female
C16.0 Cardia, NOS	97	44
C16.1 Fundus of stomach	4	2
C16.2 Body of stomach	9	3
C16.3 Gastric antrum	29	18
C16.4 Pylorus	26	11
C16.5 Lesser curvature of stomach, NOS	3	0
C16.6 Greater curvature of stomach, NOS	5	1
C16.8 Overl. lesion of stomach	2	3
C16.9 Stomach, NOS	165	110
Total	340	192

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	39	27
8001 Tumor cells, malignant	0	1
8010 Carcinoma, NOS	31	22
8032 Spindle cell carcinoma, NOS	1	3
8070 Squamous cell carcinoma, NOS	27	24
8076 Squamous cell carcinoma, microinvasive	1	0
8140 Adenocarcinoma, NOS	192	72
8142 Linitis plastica	1	0
8144 Adenocarcinoma, intestinal type	6	5
8145 Carcinoma, diffuse type	0	2
8153 Gastrinoma, malignant	4	4
8190 Trabecular adenocarcinoma	2	0
8211 Tubular adenocarcinoma	0	1
8246 Neuroendocrine carcinoma, NOS	3	4
8480 Mucinous adenocarcinoma	2	1
8490 Signet ring cell carcinoma	11	10
8631 Sertoli-Leydig cell tumor, poorly differentiate	0	1
8801 Spindle cell sarcoma	0	1
8804 Epithelioid sarcoma	0	1
8850 Liposarcoma, NOS	1	0
8936 Gastrointestinal stromal sarcoma	19	13
Total	340	192




Figure 27: Age Specific Incidence Rates of Stomach cancer in Sri Lanka, 2022



Figure 28: Age Standardized Incidence Rates of Stomach cancer in Sri Lanka, 2005-2022

Table 19: Colon and rectum cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	1564	9.7	13.8	1.8
Female	1519	7.9	11.0	1.5

ASR – Age Standardized Incidence Rate per 100, 000 population

Cum. Rate (0-74 years) per 100, 000 population

ICD 10 code and site	Male	Female
C18.0 Cecum	47	55
C18.1 Appendix	22	36
C18.2 Ascending colon	55	46
C18.3 Hepatic flexure of colon	13	10
C18.4 Transverse colon	35	19
C18.5 Splenic flexure of colon	10	11
C18.6 Descending colon	22	14
C18.7 Sigmoid colon	276	287
C18.8 Overl. lesion of colon	3	4
C18.9 Colon, NOS	240	265
C19.9 Rectosigmoid junction	111	134
C20.9 Rectum, NOS	730	638
Total	1564	1519

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	92	78
8001 Tumor cells, malignant	1	2
8002 Malignant tumor, small cell type	1	0
8010 Carcinoma, NOS	146	146
8031 Giant cell carcinoma	0	1
8032 Spindle cell carcinoma, NOS	5	0
8050 Papillary carcinoma, NOS	0	2
8070 Squamous cell carcinoma, NOS	43	31
8071 Squamous cell carcinoma, keratinizing, NOS	1	0
8083 Basaloid squamous cell carcinoma	3	1
8140 Adenocarcinoma, NOS	1163	1144
8141 Scirrhus adenocarcinoma	0	1
8144 Adenocarcinoma, intestinal type	24	22
8190 Trabecular adenocarcinoma	0	1
8210 Adenocarcinoma in adenomatous polyp	0	2
8211 Tubular adenocarcinoma	7	1
8220 Adenocarcinoma in adenomatous polyposis	0	1
8243 Goblet cell carcinoid	2	2
8244 Composite carcinoid	1	0
8246 Neuroendocrine carcinoma, NOS	18	12
8261 Adenocarcinoma in villous adenoma	1	0

ICD 10 code and histology	Male	Female
8263 Adenocarcinoma in tubulovillous adenoma	2	3
8310 Clear cell adenocarcinoma, NOS	0	1
8430 Mucoepidermoid carcinoma	2	1
8470 Mucinous cystadenocarcinoma, NOS	0	1
8480 Mucinous adenocarcinoma	38	43
8481 Mucin-producing adenocarcinoma	1	0
8490 Signet ring cell carcinoma	5	10
8550 Acinar cell carcinoma	2	0
8560 Adenosquamous carcinoma	2	2
8575 Metaplastic carcinoma, NOS	0	1
8720 Malignant melanoma, NOS (except juvenile melano	0	2
8770 Mixed epithelioid and spindle cell melanoma	0	1
8800 Sarcoma, NOS	0	2
8852 Myxoid liposarcoma	1	0
8894 Angiomyosarcoma	0	1
8936 Gastrointestinal stromal sarcoma	1	2
8980 Carcinosarcoma, NOS	1	0
9120 Hemangiosarcoma	0	1
9364 Peripheral neuroectodermal tumor	1	1
Total	1564	1519




Figure 29: Age Specific Incidence Rates of Colon and rectum cancer in Sri Lanka, 2022




Figure 30: Age Standardized Incidence Rates of Colon and rectum cancer in Sri Lanka, 2005-2022

Table 20: Laryngeal cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	600	3.7	5.3	0.7
Female	63	0.3	0.5	0.1

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C32.0 Glottis	243	28
C32.1 Supraglottis	177	20
C32.2 Subglottis	13	1
C32.3 Laryngeal cartilage	17	0
C32.8 Overl. lesion of larynx	2	0
C32.9 Larynx, NOS	148	14
Total	600	63

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	28	1
8010 Carcinoma, NOS	29	3
8032 Spindle cell carcinoma, NOS	13	2
8041 Small cell carcinoma, NOS	2	0
8070 Squamous cell carcinoma, NOS	508	56
8071 Squamous cell carcinoma, keratinizing, NOS	10	1
8076 Squamous cell carcinoma, microinvasive	2	0
8083 Basaloid squamous cell carcinoma	1	0
8140 Adenocarcinoma, NOS	7	0
Total	600	63




Figure 31: Age Specific Incidence Rates of Laryngeal cancer in Sri Lanka, 2022



Figure 32: Age Standardized Incidence Rates of Laryngeal cancer in Sri Lanka, 2005-2022

Table 21: Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	1381	8.6	12.3	1.7
Female	553	2.9	4.1	0.5

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C33.9 Trachea	10	4
C34.0 Main bronchus	41	20
C34.1 Upper lobe, lung	145	36
C34.2 Middle lobe, lung	16	4
C34.3 Lower lobe, lung	36	35
C34.8 Overl. lesion of lung	1	4
C34.9 Lung, NOS	1132	450
Total	1381	553

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	157	56
8001 Tumor cells, malignant	1	1
8002 Malignant tumor, small cell type	2	0
8004 Malignant tumor, spindle cell type	0	1
8010 Carcinoma, NOS	229	74
8012 Large cell carcinoma, NOS	5	0
8020 Carcinoma, undifferentiated, NOS	1	0
8032 Spindle cell carcinoma, NOS	7	2
8041 Small cell carcinoma, NOS	92	9
8042 Oat cell carcinoma	0	1
8043 Small cell carcinoma, fusiform cell	1	0
8046 Non-small cell carcinoma	212	71
8050 Papillary carcinoma, NOS	0	1
8070 Squamous cell carcinoma, NOS	273	39
8071 Squamous cell carcinoma, keratinizing, NOS	4	0
8075 Squamous cell carcinoma, adenoid	0	1
8076 Squamous cell carcinoma, microinvasive	2	0
8082 Lymphoepithelial carcinoma	1	0
8084 Squamous cell carcinoma, clear cell type	0	1
8140 Adenocarcinoma, NOS	341	234
8200 Adenoid cystic carcinoma	5	5
8230 Solid carcinoma, NOS	0	1
8240 Carcinoid tumor, NOS	1	9
8246 Neuroendocrine carcinoma, NOS	8	5
8249 A typical carcinoid tumor	1	1
8250 Bronchiolo-alveolar adenocarcinoma, NOS	10	0
8252 Bronchiolo-alveolar carcinoma, NOS	1	1

ICD 10 code and histology		Male	Female
8260	Papillary adenocarcinoma, NOS	0	2
8310	Clear cell adenocarcinoma, NOS	0	2
8430	Mucoepidermoid carcinoma	0	2
8440	Cystadenocarcinoma, NOS	1	0
8480	Mucinous adenocarcinoma	7	15
8490	Signet ring cell carcinoma	0	1
8550	Acinar cell carcinoma	6	7
8551	Acinar cell cystadenocarcinoma	3	5
8560	Adenosquamous carcinoma	0	1
8575	Metaplastic carcinoma, NOS	1	0
8800	Sarcoma, NOS	6	2
8802	Giant cell sarcoma (except of bone)	1	0
8803	Small cell sarcoma	1	0
8806	Desmoplastic small round cell tumor	0	1
8980	Carcinosarcoma, NOS	1	1
9170	Lymphangiosarcoma	0	1
Total		1381	553




Figure 33: Age Specific Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2022



Figure 34: Age Standardized Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2005-2022

Table 22: Skin cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	300	1.9	2.6	0.3
Female	316	1.7	2.3	0.3

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C43.0 Malignant melanoma of lip	0	1
C43.1 Malignant melanoma of eyelid, including canthus	0	2
C43.3 Malignant melanoma of unspecified parts of face	2	4
C43.4 Malignant melanoma of scalp and neck	2	0
C43.5 Malignant melanoma of trunk	1	4
C43.6 Malignant melanoma upper limb. Including shoulder	2	3
C43.7 Malignant melanoma lower limb. Including hip	11	23
C43.9 Malignant melanoma of skin unspecified	11	14
C44.0 Skin of lip, NOS	7	6
C44.1 Eyelid	19	12
C44.2 External ear	7	10
C44.3 Skin, other & unspecified parts of face	25	43
C44.4 Skin of trunk	25	27
C44.5 Skin of upper limb and shoulder	28	35
C44.6 Skin of upper limb and shoulder	18	14
C44.7 Skin of lower limb and hip	81	40
C44.8 Overlapping lesion of skin	1	0
C44.9 Skin, NOS	60	78
Total	300	316

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	11	15
8004 Malignant tumor, spindle cell type	0	1
8010 Carcinoma, NOS	8	16
8011 Epithelioma, malignant	0	2
8022 Pleomorphic carcinoma	1	0
8031 Giant cell carcinoma	1	0
8032 Spindle cell carcinoma, NOS	6	11
8050 Papillary carcinoma, NOS	0	1
8051 Verrucous carcinoma, NOS	1	0
8070 Squamous cell carcinoma, NOS	159	94
8071 Squamous cell carcinoma, keratinizing, NOS	4	2
8072 Squamous cell carcinoma, large cell, nonkeratinizing	1	0
8075 Squamous cell carcinoma, adenoid	1	0
8076 Squamous cell carcinoma, microinvasive	1	0
8083 Basaloid squamous cell carcinoma	1	3
8090 Basal cell carcinoma, NOS	42	69
8091 Multifocal superficial basal cell carcinoma	2	3
8092 Infiltrating basal cell carcinoma, NOS	1	0
8094 Basosquamous carcinoma	2	2
8095 Metatypical carcinoma	1	2
8097 Basal cell carcinoma, nodular	7	11
8098 Adenoid basal carcinoma	0	1
8102 Trichilemmocarcinoma	1	0
8140 Adenocarcinoma, NOS	4	4
8200 Adenoid cystic carcinoma	1	3
8247 Merkel cell carcinoma	0	2
8260 Papillary adenocarcinoma, NOS	0	1
8401 Apocrine adenocarcinoma	0	1
8402 Nodular hidradenoma, malignant	0	3
8403 Malignant eccrine spiradenoma	1	0
8410 Sebaceous adenocarcinoma	8	9
8542 Paget disease, extramammary (except Paget disease)	0	1
8720 Malignant melanoma, NOS (except juvenile melanoma)	18	43
8721 Nodular melanoma	2	3
8723 Malignant melanoma, regressing	5	4
8730 Amelanotic melanoma	2	1
8744 Acral lentiginous melanoma, malignant	1	0
8745 Desmoplastic melanoma, malignant	1	0
8832 Dermatofibrosarcoma, NOS	5	6
8833 Pigmented dermatofibrosarcoma protuberans	1	2
Total	300	316




Figure 35: Age Specific Incidence Rates of Skin cancer in Sri Lanka, 2022




Figure 36: Age Standardized Incidence Rates of Skin cancer in Sri Lanka, 2005-2022

Table 23: Breast cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	188	1.2	1.6	0.2
Female	5447	28.4	40.3	4.9

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C50.0 Nipple	2	36
C50.1 Central portion of breast	1	61
C50.2 Upper-inner quadrant of breast	6	131
C50.3 Lower-inner quadrant of breast	0	56
C50.4 Upper-outer quadrant of breast	5	303
C50.5 Lower-outer quadrant of breast	0	80
C50.6 Axillary tail of breast	4	49
C50.8 Overlapping lesion of breast	2	34
C50.9 Breast, NOS	168	4697
Total	188	5447

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	4	169
8001 Tumor cells, malignant	0	10
8002 Malignant tumor, small cell type	0	1
8004 Malignant tumor, spindle cell type	0	1
8005 Malignant tumor, clear cell type	0	4
8010 Carcinoma, NOS	46	1455
8011 Epithelioma, malignant	0	1
8013 Large cell neuroendocrine carcinoma	0	1
8020 Carcinoma, undifferentiated, NOS	0	1
8021 Carcinoma, anaplastic, NOS	0	1
8022 Pleomorphic carcinoma	1	1
8030 Giant cell and spindle cell carcinoma	0	1
8032 Spindle cell carcinoma, NOS	0	2
8050 Papillary carcinoma, NOS	1	30
8070 Squamous cell carcinoma, NOS	2	21
8076 Squamous cell carcinoma, microinvasive	6	16
8082 Lymphoepithelial carcinoma	0	1
8140 Adenocarcinoma, NOS	6	79
8201 Cribriform carcinoma, NOS	0	4
8211 Tubular adenocarcinoma	0	7
8230 Solid carcinoma, NOS	0	1
8260 Papillary adenocarcinoma, NOS	0	10
8430 Mucoepidermoid carcinoma	0	1
8480 Mucinous adenocarcinoma	2	38

ICD 10 code and histology		Male	Female
8500	Infiltrating duct carcinoma, NOS	80	3090
8502	Secretory carcinoma of breast	1	15
8503	Intraductal papillary adenocarcinoma with invas	1	21
8504	Intracystic carcinoma, NOS	0	1
8510	Medullary carcinoma, NOS	0	4
8513	Atypical medullary carcinoma	0	1
8514	Duct carcinoma, desmoplastic type	29	279
8520	Lobular carcinoma, NOS	3	109
8521	Infiltrating ductular carcinoma	3	19
8522	Infiltrating duct and lobular carcinoma	0	2
8524	Infiltrating lobular mixed with other types of	0	2
8525	Polymorphous low-grade adenocarcinoma	1	1
8530	Inflammatory carcinoma	0	2
8540	Paget disease, mammary	1	3
8541	Paget disease and infiltrating duct carcinoma	0	2
8543	Paget disease and intraductal carcinoma of breast	0	3
8550	Acinar cell carcinoma	1	0
8560	Adenosquamous carcinoma	0	1
8575	Metaplastic carcinoma, NOS	0	14
8800	Sarcoma, NOS	0	2
8894	Angiomyosarcoma	0	1
8980	Carcinosarcoma, NOS	0	2
9020	Phyllodes tumor, malignant	0	15
9120	Hemangiosarcoma	0	1
9170	Lymphangiosarcoma	0	1
Total		188	5447




Figure 37: Age Specific Incidence Rates of Breast cancer in Sri Lanka, 2022



Figure 38: Age Standardized Incidence Rates of Breast cancer in Sri Lanka, 2005-2022

Table 24: Cervix uteri cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Female	1226	6.4	8.9	1.1

ASR - Age Standardized Incidence Rate per 100,000 population
Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Female
C53.0 Endocervix	47
C53.1 Exocervix	15
C53.8 Overl. lesion of cervix uteri	17
C53.9 Cervix uteri	1147
Total	1226

ICD 10 code and histology	Female
8000 Neoplasm, malignant	52
8002 Malignant tumor, small cell type	1
8010 Carcinoma, NOS	129
8014 Large cell carcinoma with rhabdoid phenotype Spindle cell	1
8032 carcinoma, NOS	13
8050 Papillary carcinoma, NOS	3
8052 Papillary squamous cell carcinoma	4
8070 Squamous cell carcinoma, NOS	736
8071 Squamous cell carcinoma, keratinizing, NOS Squamous cell	76
8072 carcinoma, large cell, nonkeratinizing	55
8073 Squamous cell carcinoma, small cell, nonkeratinizing	2
8075 Squamous cell carcinoma, adenoid	1
8076 Squamous cell carcinoma, microinvasive	4
8083 Basaloid squamous cell carcinoma	8
8084 Squamous cell carcinoma, clear cell type	1
8098 Adenoid basal carcinoma	2
8140 Adenocarcinoma, NOS	105
8190 Trabecular adenocarcinoma	1
8246 Neuroendocrine carcinoma, NOS	2
8260 Papillary adenocarcinoma, NOS	1
8310 Clear cell adenocarcinoma, NOS	1
8380 Endometrioid adenocarcinoma, NOS	15
8384 Adenocarcinoma, endocervical type	3
8480 Mucinous adenocarcinoma	5
8560 Adenosquamous carcinoma	2
8890 Leiomyosarcoma, NOS	1
8900 Rhabdomyosarcoma, NOS	1
8910 Embryonal rhabdomyosarcoma, NOS	1
Total	1226




Figure 39: Age Specific Incidence Rates of Cervical cancer in Sri Lanka, 2022




Figure 40: Age Standardized Incidence Rates of Cervical cancer in Sri Lanka, 2005-2022

Table 25: Uterine cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Female	1238	6.5	9.2	1.2

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Female
C54.0 Isthmus uteri	5
C54.1 Endometrium	895
C54.2 Myometrium	3
C54.3 Fundus uteri	1
C54.8 Overlapping lesion of corpus uteri	1
C54.9 Corpus uteri	59
C55.9 Uterus, NOS	274
Total	1238

ICD 10 code and histology	Female
8000 Neoplasm, malignant	70
8010 Carcinoma, NOS	97
8032 Spindle cell carcinoma, NOS	3
8050 Papillary carcinoma, NOS	5
8070 Squamous cell carcinoma, NOS	50
8071 Squamous cell carcinoma, keratinizing, NOS	3
8072 Squamous cell carcinoma, large cell, nonkeratinizing	4
8076 Squamous cell carcinoma, microinvasive	1
8083 Basaloid squamous cell carcinoma	1
8120 Transitional cell carcinoma, NOS	1
8140 Adenocarcinoma, NOS	208
8141 Scirrhous adenocarcinoma	1
8200 Adenoid cystic carcinoma	1
8214 Parietal cell carcinoma	1
8260 Papillary adenocarcinoma, NOS	5
8310 Clear cell adenocarcinoma, NOS	12
8320 Granular cell carcinoma	1
8380 Endometrioid adenocarcinoma, NOS	653
8381 Endometrioid adenofibroma, malignant	1
8383 Endometrioid adenocarcinoma, ciliated cell variant	2
8440 Cystadenocarcinoma, NOS	4
8441 Serous cystadenocarcinoma, NOS	1
8480 Mucinous adenocarcinoma	3
8560 Adenosquamous carcinoma	2
8570 Adenocarcinoma with squamous metaplasia	2
8800 Sarcoma, NOS	18

ICD 10 code and histology		Female
8801	Spindle cell sarcoma	1
8850	Liposarcoma, NOS	2
8890	Leiomyosarcoma, NOS	24
8891	Epithelioid leiomyosarcoma	1
8896	Myxoid leiomyosarcoma	1
8900	Rhabdomyosarcoma, NOS	1
8930	Endometrial stromal sarcoma, NOS	19
8931	Endometrial stromal sarcoma, low grade	1
8933	Adenosarcoma	3
8935	Stromal sarcoma, NOS	5
8950	Mullerian mixed tumor	3
8980	Carcinosarcoma, NOS	25
9014	Serous adenocarcinofibroma	1
9580	Granular cell tumor, malignant	1
Total		1238




Figure 41: Age Specific Incidence Rates of Uterine cancer in Sri Lanka, 2022




Figure 42: Age Standardized Incidence Rates of Uterine cancer in Sri Lanka, 2006-2022

Table 26: Ovary cancer incidence in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Female	1112	5.8	8.4	1.0

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Female
C56.9 Ovary	1112
Total	1112

ICD 10 code and histology	Female
8000 Neoplasm, malignant	84
8001 Tumor cells, malignant	7
8005 Malignant tumor, clear cell type	1
8010 Carcinoma, NOS	171
8032 Spindle cell carcinoma, NOS	2
8050 Papillary carcinoma, NOS	10
8070 Squamous cell carcinoma, NOS	26
8071 Squamous cell carcinoma, keratinizing, NOS	3
8072 Squamous cell carcinoma, large cell, nonkeratinizing	1
8140 Adenocarcinoma, NOS	132
8200 Adenoid cystic carcinoma	1
8240 Carcinoid tumor, NOS	1
8246 Neuroendocrine carcinoma, NOS	1
8260 Papillary adenocarcinoma, NOS	11
8310 Clear cell adenocarcinoma, NOS	31
8320 Granular cell carcinoma	9
8380 Endometrioid adenocarcinoma, NOS	56
8440 Cystadenocarcinoma, NOS	3
8441 Serous cystadenocarcinoma, NOS	304
8450 Papillary cystadenocarcinoma, NOS	7
8460 Papillary serous cystadenocarcinoma	47
8461 Serous surface papillary carcinoma	2
8470 Mucinous cystadenocarcinoma, NOS	36
8471 Papillary mucinous cystadenocarcinoma	3
8480 Mucinous adenocarcinoma	29
8482 Mucinous adenocarcinoma, endocervical type	2
8510 Medullary carcinoma, NOS	1
8560 Adenosquamous carcinoma	1
8620 Granulosa cell tumor, malignant	25

ICD 10 code and histology		Female
8631	Sertoli-Leydig cell tumor, poorly differentiate	9
8640	Sertoli cell carcinoma	2
8800	Sarcoma, NOS	3
8890	Leiomyosarcoma, NOS	2
8935	Stromal sarcoma, NOS	1
8980	Carcinosarcoma, NOS	3
9000	Brenner tumor, malignant	1
9014	Serous adenocarcinofibroma	16
9060	Dysgerminoma	22
9064	Germinoma	5
9071	Yolk sac tumor	6
9080	Teratoma, malignant, NOS	17
9081	Teratocarcinoma	1
9082	Malignant teratoma, undifferentiated	1
9085	Mixed germ cell tumor	9
9090	Struma ovarii, malignant	4
9580	Granular cell tumor, malignant	3
Total		1112




Figure 43: Age Specific Incidence Rates of Ovarian cancer in Sri Lanka, 2022




Figure 44: Age Standardized Incidence Rates of Ovarian cancer in Sri Lanka, 2005-2022

Table 27: Prostate cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	1226	7.6	11.1	1.5

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male
C61.9 Prostate gland	1226
Total	1226

ICD 10 code and histology	Male
8000 Neoplasm, malignant	95
8001 Tumor cells, malignant	2
8010 Carcinoma, NOS	173
8032 Spindle cell carcinoma, NOS	2
8046 Non-small cell carcinoma	1
8050 Papillary carcinoma, NOS	2
8070 Squamous cell carcinoma, NOS	16
8075 Squamous cell carcinoma, adenoid	1
8120 Transitional cell carcinoma, NOS	6
8130 Papillary transitional cell carcinoma	3
8140 Adenocarcinoma, NOS	523
8190 Trabecular adenocarcinoma	1
8230 Solid carcinoma, NOS	1
8246 Neuroendocrine carcinoma, NOS	1
8480 Mucinous adenocarcinoma	1
8500 Infiltrating duct carcinoma, NOS	5
8550 Acinar cell carcinoma	339
8551 Acinar cell cystadenocarcinoma	52
8570 Adenocarcinoma with squamous metaplasia	1
8802 Giant cell sarcoma (except of bone)	1
Total	1226




Figure 45: Age Specific Incidence Rates of Prostate cancer in Sri Lanka, 2022



Figure 46: Age Standardized Incidence Rates of Prostate cancer, 2005-2022

Table 28 : Urinary bladder cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	573	3.6	5.1	0.7
Female	161	0.8	1.1	0.1

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C67.0 Trigone of urinary bladder	9	0
C67.1 Dome of urinary bladder	1	1
C67.2 Lateral wall of urinary bladder	7	2
C67.3 Anterior wall of urinary bladder	1	2
C67.4 Posterior wall of urinary bladder	3	3
C67.5 Bladder neck	18	9
C67.6 Ureteric orifice	7	1
C67.7 Urachus	3	5
C67.8 Overlapping lesion of bladder	6	2
C67.9 Urinary bladder, NOS	518	136
Total	573	161

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	42	15
8001 Tumor cells, malignant	2	0
8010 Carcinoma, NOS	84	24
8032 Spindle cell carcinoma, NOS	1	0
8041 Small cell carcinoma, NOS	2	0
8050 Papillary carcinoma, NOS	34	6
8052 Papillary squamous cell carcinoma	0	1
8070 Squamous cell carcinoma, NOS	22	7
8076 Squamous cell carcinoma, microinvasive	1	0
8120 Transitional cell carcinoma, NOS	202	51
8122 Transitional cell carcinoma, spindle cell	0	1
8130 Papillary transitional cell carcinoma	152	42
8131 Transitional cell carcinoma, micropapillary	1	1
8140 Adenocarcinoma, NOS	21	5
8246 Neuroendocrine carcinoma, NOS	0	1
8260 Papillary adenocarcinoma, NOS	3	2
8480 Mucinous adenocarcinoma	0	3
8490 Signet ring cell carcinoma	0	1
8503 Intraductal papillary adenocarcinoma with invas	0	1
8550 Acinar cell carcinoma	3	0
8551 Acinar cell cystadenocarcinoma	1	0
9503 Neuroepithelioma, NOS	2	0
Total	573	161




Figure 47: Age Specific Incidence Rates of Urinary bladder cancer in Sri Lanka, 2022




Figure 48: Age Standardized Incidence Rates of Urinary bladder cancer in Sri Lanka, 2005-2022

Table 29: Thyroid gland cancer incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	560	3.5	4.8	0.5
Female	2369	12.3	18.4	1.7

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C73.9 Thyroid gland	560	2369
Total	560	2369

ICD 10 code and histology	Male	Female
8000 Neoplasm, malignant	23	74
8001 Tumor cells, malignant	0	4
8005 Malignant tumor, clear cell type	0	2
8010 Carcinoma, NOS	43	145
8021 Carcinoma, anaplastic, NOS	9	11
8022 Pleomorphic carcinoma	0	2
8034 Polygonal cell carcinoma	1	1
8050 Papillary carcinoma, NOS	211	826
8052 Papillary squamous cell carcinoma	0	3
8070 Squamous cell carcinoma, NOS	10	9
8140 Adenocarcinoma, NOS	2	6
8260 Papillary adenocarcinoma, NOS	130	460
8290 Oxyphilic adenocarcinoma	2	9
8320 Granular cell carcinoma	0	1
8330 Follicular adenocarcinoma, NOS	36	195
8331 Follicular adenocarcinoma, well differentiated	0	2
8335 Follicular carcinoma, minimally invasive	22	148
8337 Insular carcinoma	0	1
8340 Papillary carcinoma, follicular variant	16	87
8341 Papillary microcarcinoma	42	363
8343 Papillary carcinoma, encapsulated	0	7
8344 Papillary carcinoma, columnar cell	0	1
8345 Medullary carcinoma with amyloid stroma	0	1
8430 Mucoepidermoid carcinoma	0	1
8510 Medullary carcinoma, NOS	13	9
8894 Angiomyosarcoma	0	1
Total	560	2369




Figure 49 Age Specific Incidence Rates of Thyroid cancer in Sri Lanka, 2022



Figure 50: Age Standardized Incidence Rates of Thyroid cancer in Sri Lanka, 2005-2022

Table 30: Lymphoma incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	601	3.7	5.3	0.6
Female	428	2.2	3.3	0.4

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C810 Hodgkin lymphoma, nodular lymphocyte predominance	3	1
C811 Hodgkin lymphoma, nodular sclerosis, NOS	10	7
C812 Hodgkin lymphoma, mixed cellularity, NOS	7	1
C814 Hodgkin lymphoma, lymphocyte-rich	2	3
C819 Hodgkin lymphoma, unspecified	128	91
C820 Follicular lymphoma, grade 1	10	2
C821 Follicular lymphoma, grade 2	1	6
C822 Follicular lymphoma, grade 3	0	1
C829 Follicular lymphoma, NOS	32	22
C830 Malignant lymphoma, small B lymphocytic, NOS	11	5
C831 Mantle cell lymphoma	5	3
C833 Malignant lymphoma, large B-cell, diffuse, NOS	37	25
C835 Lymphoblastic (diffuse) lymphoma	18	9
C837 Burkitt lymphoma, NOS	3	3
C838 Primary effusion lymphoma	0	1
C840 Mycosis fungoides	6	10
C841 Sezary syndrome	1	0
C844 Mature T-cell lymphoma, NOS	7	3
C846 Anaplastic large cell lymphoma, T cell and Null cell type	11	8
C848 Cutaneous T-cell lymphoma, NOS	2	3
C852 Mediastinal large B-cell lymphoma	2	4
C857 Composite Hodgkin and non-Hodgkin lymphoma	10	13
C859 Malignant lymphoma, non-Hodgkin, unspecified	285	200
C962 Malignant mastocytosis	0	1
C964 Follicular dendritic cell sarcoma	0	1
C966 Langerhans cell histiocytosis, disseminated	3	2
C968 Histiocytic sarcoma	7	3
Total	601	428

ICD 10 code and histology		Male	Female
9590	Malignant lymphoma, NOS	54	43
9591	Malignant lymphoma, non-Hodgkin, NOS	231	157
9596	Composite Hodgkin and non-Hodgkin lymphoma	10	13
9650	Hodgkin lymphoma, NOS	126	91
9651	Hodgkin lymphoma, lymphocyte-rich	2	3
9652	Hodgkin lymphoma, mixed cellularity, NOS	7	1
9659	Hodgkin lymphoma, nodular lymphocyte predominance	3	1
9661	Hodgkin granuloma	2	0
9663	Hodgkin lymphoma, nodular sclerosis, NOS	10	7
9670	Malignant lymphoma, small B lymphocytic, NOS	4	2
9671	Malignant lymphoma, lymphoplasmacytic	7	2
9673	Mantle cell lymphoma	5	3
9678	Primary effusion lymphoma	0	1
9679	Mediastinal large B-cell lymphoma	2	4
9680	Malignant lymphoma, large B-cell, diffuse, NOS	36	24
9684	Malignant lymphoma, large B-cell, diffuse, immunoblastic	1	1
9687	Burkitt lymphoma, NOS	3	3
9689	Splenic marginal zone B-cell lymphoma	0	1
9690	Follicular lymphoma, NOS	32	22
9691	Follicular lymphoma, grade 2	1	6
9695	Follicular lymphoma, grade 1	10	2
9698	Follicular lymphoma, grade 3	0	1
9700	Mycosis fungoides	6	10
9701	Sezary syndrome	1	0
9702	Mature T-cell lymphoma, NOS	7	3
9709	Cutaneous T-cell lymphoma, NOS	2	3
9714	Anaplastic large cell lymphoma, T cell and	11	8
9727	Precursor cell lymphoblastic lymphoma, NOS	1	0
9728	Precursor B-cell lymphoblastic lymphoma	0	1
9729	Precursor T-cell lymphoblastic lymphoma	17	8
9741	Malignant mastocytosis	0	1
9750	Malignant histiocytosis	6	2
9754	Langerhans cell histiocytosis, disseminated	3	2
9755	Histiocytic sarcoma	1	1
9758	Follicular dendritic cell sarcoma	0	1
Total		601	428




Figure 51: Age Specific Incidence Rates of Lymphoma in Sri Lanka, 2022




Figure 52: Age Standardized Incidence Rates of Lymphoma in Sri Lanka, 2011-2022

Table 31: Leukaemia incidence data in Sri Lanka, 2022

Group	Number	%	ASR	Cum. Rate
Male	484	3.0	4.6	0.4
Female	395	2.1	3.3	0.3

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site	Male	Female
C910 Acute lymphoblastic leukemia	155	112
C911 B-cell chronic lymphocytic leukemia/small lymph	5	6
C913 Prolymphocytic leukemia of B cell type	1	2
C914 Hairy cell leukemia	6	3
C915 Adult T-cell leukemia/lymphoma (HTLV-1 positive	0	1
C918 Mature B-cell leukemia Burkitt -Type	9	9
C919 Lymphoid leukemia, NOS	5	2
C920 Acute myeloid leukemia with maturation	136	133
C921 Acute myeloblastic leukaemia (AML)	62	45
C922 Atypical chronic myeloid leukemia, BCR/ABL-positive	1	0
C924 Acute promyelocytic leukemia, (PML)	2	7
C925 Acute myelomonocytic leukemia	1	2
C928 Acute myeloid leukemia with multilineage dysplasia	1	0
C929 Myeloid leukemia, NOS	10	4
C931 Chronic myelomonocytic leukemia, NOS	3	2
C933 Juvenile myelomonocytic leukemia	3	1
C940 Acute myeloid leukemia, M6 type	22	14
C942 Acute megakaryoblastic leukemia	0	2
C944 Acute panmyelosis with myelofibrosis	4	1
C947 Other specific leukemia	0	1
C950 Acute leukemia, NOS	51	37
C959 Leukemia, NOS	7	11
Total	484	395

ICD 10 code and histology		Male	Female
9800	Leukemia, NOS	7	11
9801	Acute leukemia, NOS	50	37
9805	Acute biphenotypic leukemia	1	0
9820	Lymphoid leukemia, NOS	5	2
9823	B-cell chronic lymphocytic leukemia/small lymph	5	6
9826	Burkitt cell leukemia	9	9
9827	Adult T-cell leukemia/lymphoma (HTLV-1 positive	0	1
9832	Prolymphocytic leukemia, NOS	1	2
9835	Precursor cell lymphoblastic leukemia, NOS	8	9
9836	Precursor B-cell lymphoblastic leukemia	106	83
9837	Precursor T-cell lymphoblastic leukemia	41	20
9840	Acute myeloid leukemia, M6 type	22	14
9860	Myeloid leukemia, NOS	10	4
9861	Acute myeloid leukemia, NOS	131	128
9863	Chronic myeloid leukemia, NOS	61	43
9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	2	7
9867	Acute myelomonocytic leukemia	1	2
9870	Acute basophilic leukemia	0	1
9872	Acute myeloid leukemia, minimal differentiation	1	0
9873	Acute myeloid leukemia without maturation	1	0
9874	Acute myeloid leukemia with maturation	1	3
9875	Chronic myelogenous leukemia, BCR/ABL	1	2
9876	Atypical chronic myeloid leukemia,	1	0
9895	Acute myeloid leukemia with multilineage dyspla	1	0
9910	Acute megakaryoblastic leukemia	0	2
9931	Acute panmyelosis with myelofibrosis	4	1
9940	Hairy cell leukemia	6	3
9945	Chronic myelomonocytic leukemia, NOS	3	2
9946	Juvenile myelomonocytic leukemia	3	1
9984	Refractory anemia with excess blasts in transformation	2	2
Total		484	395




Figure 53: Age Specific Incidence Rates of Leukaemia in Sri Lanka, 2022



Figure 54: Age Standardized Incidence Rates of Leukaemia in Sri Lanka, 2011–2022

Clinical Staging at the point of diagnosis - 2022




Figure 55: Clinical staging at the point of diagnosis of breast cancer




Figure 56: Clinical staging at the point of diagnosis of cervical cancer




Figure 57: Clinical staging at the point of diagnosis of lip, tongue and mouth cancer

Table 32: Basis of diagnosis of cancer patients in Sri Lanka, 2022

Basis of diagnosis	Frequency	Percentage
Diagnosed microscopically		
Histology of primary	33633	93.8
Histology of metastasis	918	2.6
Cytology/Hematology only	238	0.7
Subtotal	34789	97.1
Diagnosed non-microscopically		
Clinical investigation including X-ray, USS, CT, etc. (imaging only)	183	0.5
Death certificate only	707	2.0
Clinical only	6	0
Specific biochemical/immunological test only	10	0
Exploratory surgery	1	0
Subtotal	907	2.5
Unknown/Not recorded	159	0.4
Total	35855	100




Figure 58: Basis of diagnosis of cancer in Sri Lanka, 2022




Figure 59: Percentage of newly detected cancer patients who received different types of treatment, 2022

Table 33: Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2022

According to International Classification of Childhood Cancer third edition (ICCC-3) by sex

ICCC-3 Site Group		ICD-O3 Histology			Male	Female	Total	
I	Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	a	Lymphoid leukaemia	9820	Lymphoid leukemia, NOS	5	2	7
				9826	Burkitt cell leukemia	1	0	1
				9835	Precursor cell lymphoblastic leukemia, NOS	0	3	3
				9836	Precursor B-cell lymphoblastic leukemia	88	64	152
				9837	Precursor T-cell lymphoblastic leukemia	29	16	45
		b	Acute myeloid leukaemia	9840	Acute myeloid leukemia, M6 type	2	2	4
				9861	Acute myeloid leukemia, NOS	28	16	44
				9866	Acute promyelocytic leukemia, t (15;17) (q22; q11-	1	1	2
				9867	Acute myelomonocytic leukemia	0	1	1
				9870	Acute basophilic leukemia	0	1	1
		c	Chronic myeloproliferative diseases	9863	Chronic myeloid leukemia, NOS	2	1	3
		d	Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukemia	3	1	4
		e	Unspecified and other specified leukaemia	9801	Acute leukemia, NOS	15	8	23
Total					174	116	290	
II	Lymphomas and reticuloendothelial neoplasms	a	Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	14	6	20
				9651	Hodgkin lymphoma, lymphocyte-rich	0	1	1
				9652	Hodgkin lymphoma, mixed cellularity, NOS	1	0	1
				9659	Hodgkin lymphoma, nodular lymphocyte predominant	1	0	1
				9663	Hodgkin lymphoma, nodular sclerosis, NOS	2	1	3
		b	Non-Hodgkin lymphomas (except Burkitt lymphoma	9591	Malignant lymphoma, non-Hodgkin, NOS	9	1	10
				9680	Malignant lymphoma, large B-cell, diffuse, NOS	3	2	5
				9690	Follicular lymphoma, NOS	2	0	2
				9700	Mycosis fungoides	1	2	3

ICCC-3 Site Group		ICD-O3 Histology			Male	Female	Total	
		9702	Mature T-cell lymphoma, NOS	1	0	1		
		9709	Cutaneous T-cell lymphoma, NOS	1	1	2		
		9714	Anaplastic large cell lymphoma, T cell and Null cell type	6	4	10		
		9729	Precursor T-cell lymphoblastic lymphoma	8	6	14		
		9732	Multiple myeloma	0	1	1		
	c	Burkitt lymphoma	9687	Burkitt lymphoma, NOS	3	1	4	
	d	Miscellaneous lymphoreticular neoplasms	9750	Malignant histiocytosis	6	2	8	
		9754	Langerhans cell histiocytosis, disseminated	3	0	3		
	e	Unspecified lymphomas	9590	Malignant lymphoma, NOS	1	1	2	
	Total				62	29	91	
III	CNS and miscellaneous intracranial and intraspinal neoplasms	a	Ependymomas and choroid plexus tumour	9391	Ependymoma, NOS	3	3	6
				9392	Ependymoma, anaplastic	1	1	2
				9393	Papillary ependymoma	0	2	2
				9394	Myxopapillary ependymoma	0	1	1
	b	Astrocytoma	9380	Glioma, malignant	2	2	4	
			9400	Astrocytoma, NOS	14	9	23	
			9440	Glioblastoma, NOS	1	1	2	
	c	Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	9	7	16	
			9471	Desmoplastic nodular medulloblastoma	3	2	5	
			8963	Malignant rhabdoid tumor	0	1	1	
	d	Other gliomas	9380	Glioma, malignant	9	18	27	
			9450	Oligodendroglioma, NOS	2	0	2	
			9451	Oligodendroglioma, anaplastic	0	1	1	
	e	Other specified intracranial and intraspinal neoplasms	9350	Craniopharyngioma	4	2	6	
			9351	Craniopharyngioma, adamantinomatous	1	0	1	
			9530	Meningioma, malignant	1	0	1	
			9539	Meningeal sarcomatosis	0	1	1	
	f	Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	0	2	2	
			8002	Malignant tumor, small cell type	1	0	1	
Total				51	53	104		

ICCC-3 Site Group		ICD-O3 Histology				Male	Female	Total
IV	Neuroblastoma and other peripheral nervous cell	a	Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	5	4	9
				9500	Neuroblastoma, NOS	11	9	20
		b	Other peripheral nervous cell tumour	8700	Pheochromocytoma, malignant	1	0	1
				9522	Olfactory neuroblastoma	0	1	1
Total						17	14	31
V	Retinoblastoma	5	Retinoblastoma	9510	Retinoblastoma, NOS	18	9	27
				9511	Retinoblastoma, differentiated	1	0	1
Total						19	9	28
VI	Renal tumour	a	Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	13	11	24
		b	Renal carcinoma	8312	Renal cell carcinoma, NOS	0	2	2
Total						13	13	26
VII	Hepatic tumours	a	Hepatoblastoma	8970	Hepatoblastoma	4	6	10
Total						4	6	10
VIII	Malignant bone tumours	a	Osteosarcomas	9180	Osteosarcoma, NOS	22	10	32
				9181	Chondroblast osteosarcoma	3	1	4
				9182	Fibroblastic osteosarcoma	0	1	1
				9183	Telangiectatic osteosarcoma	1	0	1
		b	Chondrosarcomas	9220	Chondrosarcoma, NOS	1	1	2
				9260	Ewing sarcoma	24	22	46
		d	Other specified malignant bone tumours	9250	Giant cell tumor of bone, malignant	2	1	3
				9261	Adamantinoma of long bones	1	0	1
		e	Unspecified malignant bone tumour	8000	Neoplasm, malignant	1	2	3
				8800	Sarcoma, NOS	0	1	1
Total						55	39	94
IX	Soft tissue and other extraosseous sarcoma	a	Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	8	5	13
				8910	Embryonal rhabdomyosarcoma, NOS	4	1	5
				8920	Alveolar rhabdomyosarcoma	0	1	1
		b	Fibrosarcoma, PNST and other fibrous neoplasms	8810	Fibrosarcoma, NOS	1	0	1
				8824	Myofibromatosis	1	0	1
				9540	Malignant peripheral nerve sheath tumor	0	1	1
				9560	Neurilemoma, malignant	0	1	1

ICCC-3 Site Group		ICD-O3 Histology			Male	Female	Total
X	d Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumour		12	2	14
		9040	Synovial sarcoma, NOS		3	1	4
		9120	Hemangiosarcoma		1	0	1
		9251	Malignant giant cell tumor of soft parts		1	0	1
		9260	Ewing sarcoma		2	2	4
		9365	Askin tumor		1	0	1
	e Unspecified soft tissue sarcomas	8800	Sarcoma, NOS		2	0	2
		8801	Spindle cell sarcoma		0	1	1
		8802	Giant cell sarcoma (except of bone)		1	0	1
		8804	Epithelioid sarcoma		0	2	2
	Total				37	17	54
	Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	a Intracranial and intraspinal germ cell tumours	9064	Germinoma	7	0	7
			9070	Embryonal carcinoma, NOS	0	1	1
			9085	Mixed germ cell tumor	0	1	1
		b Malignant extracranial and extragonadal germ cell tumours	9064	Germinoma	1	0	1
			9065	Germ cell tumor, nonseminomatous	0	2	2
			9070	Embryonal carcinoma, NOS	0	1	1
			9080	Teratoma, malignant, NOS	3	4	7
			9085	Mixed germ cell tumor	1	0	1
		c Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	11	11
			9064	Germinoma	0	2	2
			9065	Germ cell tumor, nonseminomatous	1	0	1
			9070	Embryonal carcinoma, NOS	2	0	2
			9071	Yolk sac tumor	2	3	5
			9080	Teratoma, malignant, NOS	1	7	8
			9082	Malignant teratoma, undifferentiated	1	0	1
			9085	Mixed germ cell tumor	1	6	7
		d Gonadal carcinomas	8010	Carcinoma, NOS	0	5	5
		e Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant	1	1	2
	Total				21	44	65

ICCC-3 Site Group		ICD-O3 Histology			Male	Female	Total	
XI	Other malignant epithelial neoplasms and malignant melanomas	a	Adrenocortical carcinomas	8370	Adrenal cortical carcinoma	2	1	3
		b	Thyroid carcinomas	8010	Carcinoma, NOS	0	4	4
				8050	Papillary carcinoma, NOS	7	23	30
				8260	Papillary adenocarcinoma, NOS	6	27	33
				8330	Follicular adenocarcinoma, NOS	0	3	3
				8335	Follicular carcinoma, minimally invasive	0	5	5
				8340	Papillary carcinoma, follicular variant	0	1	1
				8341	Papillary microcarcinoma	3	5	8
		c	Nasopharyngeal carcinomas	8010	Carcinoma, NOS	2	0	2
				8070	Squamous cell carcinoma, NOS	1	0	1
		d	Malignant melanomas	8720	Malignant melanoma, NOS (except juvenile melanoma)	0	1	1
		e	Skin carcinomas	8200	Adenoid cystic carcinoma	0	1	1
				8402	Nodular hidradenoma, malignant	0	1	1
		f	Other & unspecified carcinomas	8010	Carcinoma, NOS	3	4	7
				8022	Pleomorphic carcinoma	1	0	1
				8032	Spindle cell carcinoma, NOS	0	2	2
				8033	Pseudosarcomatous carcinoma	0	2	2
				8041	Small cell carcinoma, NOS	0	1	1
				8070	Squamous cell carcinoma, NOS	3	1	4
				8130	Papillary transitional cell carcinoma	0	1	1
				8140	Adenocarcinoma, NOS	1	2	3
				8243	Goblet cell carcinoid	0	1	1
				8246	Neuroendocrine carcinoma, NOS	1	2	3
				8310	Clear cell adenocarcinoma, NOS	1	0	1
				8320	Granular cell carcinoma	0	1	1
				8430	Mucoepidermoid carcinoma	1	4	5
				8452	Solid pseudopapillary carcinoma	0	2	2
				8550	Acinar cell carcinoma	1	0	1
Total					33	95	128	
XII	Other and unspecified malignant neoplasms	a	Other specified malignant tumours	8935	Stromal sarcoma, NOS	0	1	1
				8981	Carcinosarcoma, embryonal	0	1	1
		b	Other unspecified malignant tumours	8000	Neoplasm, malignant	12	4	16
				8004	Malignant tumor, spindle cell type	1	0	1
Total					13	6	19	
All site total					499	441	940	

Table 34: Overall cancer Incidence by province and district in Sri Lanka, 2022

Province	District	Male No	%	Female No	%	Total No	%
	Not known	4,316	26.3	4,687	24.1	9,003	25.0
Western		3547	21.6	4541	23.3	8088	22.6
	Colombo	1692	10.3	2098	10.8	3790	10.6
	Gampaha	1198	7.3	1527	7.8	2725	7.6
	Kalutara	657	4.0	916	4.7	1573	4.4
Central		1329	8.1	1832	9.4	3161	8.8
	Kandy	677	4.1	998	5.1	1675	4.7
	Matale	369	2.3	376	1.9	745	2.1
	Nuwara Eliya	283	1.7	458	2.4	741	2.1
Southern		1462	8.9	1770	9.1	3232	9.0
	Galle	591	3.6	790	4.1	1381	3.9
	Matara	485	3.0	579	3.0	1064	3.0
	Hambantota	386	2.4	401	2.1	787	2.2
Northern		608	3.7	688	3.5	1296	3.6
	Jaffna	372	2.3	410	2.1	782	2.2
	Kilinochchi	57	0.3	67	0.3	124	0.3
	Mannar	55	0.3	59	0.3	114	0.3
	Mullaitivu	50	0.3	52	0.3	102	0.3
	Vavuniya	74	0.5	100	0.5	174	0.5
Eastern		687	4.2	827	4.3	1514	4.2
	Ampara	298	1.8	330	1.7	628	1.8
	Batticaloa	243	1.5	301	1.5	544	1.5
	Trincomalee	146	0.9	196	1.0	342	1.0
North Western		1695	10.3	1902	9.8	3597	10.0
	Kurunegala	1267	7.7	1445	7.4	2712	7.6
	Puttalam	428	2.6	457	2.3	885	2.5
North Central		759	4.6	868	4.5	1627	4.5
	Anuradapura	529	3.2	538	2.8	1067	3.0
	Polonnaruwa	230	1.4	330	1.7	560	1.6
Uva		717	4.4	824	4.2	1541	4.3
	Badulla	456	2.8	561	2.9	1017	2.8
	Moneragala	261	1.6	263	1.4	524	1.5
Sabaragamuwa		1278	7.8	1518	7.8	2796	7.8
	Ratnapura	744	4.5	865	4.4	1609	4.5
	Kegalle	534	3.3	653	3.4	1187	3.3
Total		16398	100.0	19457	100.0	35,855	100.0

Table 35: Leading cancer incidence data by sex and district in Sri Lanka, 2022
Western Province
Leading cancer incidence data by sex in Colombo District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	204	16.8	C50	Breast	625	49.5
C18-C20	Colon and rectum	202	16.6	C73	Thyroid gland	172	13.6
C61	Prostate	183	15.1	C18-C20	Colon and rectum	163	12.9
C33-C34	Trachea, bronchus and lung	148	12.2	C54-C55	Uterus	149	11.8
C15	Oesophagus	65	5.3	C56	Ovary	122	9.7
C80-C85, C96	Lymphoma	65	5.3	C53	Cervix uteri	98	7.8
C32	Larynx	62	5.1	C33-C34	Trachea, bronchus and lung	79	6.3
C67	Bladder	54	4.4	C00-C06	Lip, tongue and mouth	72	5.7
C22	Liver and intrahepatic bile duct	54	4.4	C80-C85, C96	Lymphoma	59	4.7
C09-C014	Pharynx	53	4.4	C91 - C95	Leukaemia	48	3.8
Total		1692	139.2	Total		2098	166.2

Leading cancer incidence data by sex in Gampaha District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	232	19.6	C50	Breast	566	45.0
C18-C20	Colon and rectum	129	10.9	C73	Thyroid gland	156	12.4
C61	Prostate	108	9.1	C18-C20	Colon and rectum	117	9.3
C09-C014	Pharynx	85	7.2	C54-C55	Uterus	114	9.1
C15	Oesophagus	68	5.8	C56	Ovary	101	8.0
C33-C34	Trachea, bronchus and lung	64	5.4	C53	Cervix uteri	78	6.2
C80-C85, C96	Lymphoma	58	4.9	C91 - C95	Leukaemia	42	3.3
C73	Thyroid gland	52	4.4	C33-C34	Trachea, bronchus and lung	41	3.3
C32	Larynx	47	4.0	C00-C06	Lip, tongue and mouth	38	3.0
C91 - C95	Leukaemia	45	3.8	C80-C85, C96	Lymphoma	35	2.8
Total		1198	101.4	Total		1527	121.5

Leading cancer incidence data by sex in Kalutara District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	108	17.3	C50	Breast	271	40.6
C61	Prostate	63	11.4	C73	Thyroid gland	118	17.7
C18-C20	Colon and rectum	71	10.1	C53	Cervix uteri	80	12.0
C33-C34	Trachea, bronchus and lung	36	6.9	C18-C20	Colon and rectum	71	10.6
C80-C85, C96	Lymphoma	32	5.9	C54-C55	Uterus	71	10.6
C09-C014	Pharynx	43	5.8	C56	Ovary	45	6.7
C91 - C95	Leukaemia	37	5.3	C91 - C95	Leukaemia	32	4.8
C15	Oesophagus	16	5.1	C15	Oesophagus	32	4.8
C64	Kidney	16	3.5	C80-C85, C96	Lymphoma	23	3.4
C22	Liver and intrahepatic bile duct	33	3.0	C33-C34	Trachea, bronchus and lung	20	3.0
Total		657	105.1	Total		916	137.4

Central Province

Leading cancer incidence data by sex in Kandy District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C33-C34	Trachea, bronchus and lung	91	12.7	C50	Breast	311	39.7
C18-C20	Colon and rectum	67	9.4	C73	Thyroid gland	146	18.6
C00-C06	Lip, tongue and mouth	65	9.1	C18-C20	Colon and rectum	83	10.6
C61	Prostate	56	7.8	C56	Ovary	55	7.0
C73	Thyroid gland	53	7.4	C15	Oesophagus	52	6.6
C15	Oesophagus	50	7.0	C53	Cervix uteri	51	6.5
C91 - C95	Leukaemia	29	4.1	C54-C55	Uterus	44	5.6
C22	Liver and intrahepatic bile duct	29	4.1	C00-C06	Lip, tongue and mouth	40	5.1
C09-C014	Pharynx	27	3.8	C33-C34	Trachea, bronchus and lung	18	2.3
C80-C85, C96	Lymphoma	24	3.4	C70-C72	Brain and central nervous system	17	2.2
Total		677	94.7	Total		998	127.2

Leading cancer incidence data by sex in Matale District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	69	27.0	C50	Breast	112	40.8
C33-C34	Trachea, bronchus and lung	50	19.6	C73	Thyroid gland	45	16.4
C15	Oesophagus	38	14.9	C18-C20	Colon and rectum	37	13.5
C09-C014	Pharynx	31	12.1	C53	Cervix uteri	30	10.9
C18-C20	Colon and rectum	24	9.4	C56	Ovary	21	7.6
C61	Prostate	21	8.2	C54-C55	Uterus	21	7.6
C32	Larynx	17	6.6	C15	Oesophagus	18	6.6
C73	Thyroid gland	10	3.9	C00-C06	Lip, tongue and mouth	13	4.7
C80-C85, C96	Lymphoma	8	3.1	C33-C34	Trachea, bronchus and lung	7	2.5
C67	Bladder	7	2.7	C80-C85, C96	Lymphoma	7	2.5
Total		369	144.3	Total		376	137.0

Leading cancer incidence data by sex in Nuwara Eliya District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	55	14.7	C50	Breast	132	32.3
C15	Oesophagus	30	8.0	C73	Thyroid gland	45	11.0
C33-C34	Trachea, bronchus and lung	29	7.7	C53	Cervix uteri	41	10.0
C09-C014	Pharynx	22	4.5	C15	Oesophagus	41	10.0
C32	Larynx	17	4.0	C56	Ovary	35	8.6
C43-C44	Skin	15	4.0	C00-C06	Lip, tongue and mouth	28	6.9
C64	Kidney	11	2.9	C54-C55	Uterus	21	5.1
C61	Prostate	9	2.4	C18-C20	Colon and rectum	19	4.7
C18-C20	Colon and rectum	8	2.1	C33-C34	Trachea, bronchus and lung	10	2.4
C91 - C95	Leukaemia	8	2.1	C43-C44	Skin	9	2.2
Total		283	75.6	Total		458	112.2

Southern Province

Leading cancer incidence data by sex in Galle District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	123	22.4	C50	Breast	202	33.9
C33-C34	Trachea, bronchus and lung	51	9.3	C73	Thyroid gland	163	27.3
C61	Prostate	47	8.5	C18-C20	Colon and rectum	64	10.7
C18-C20	Colon and rectum	41	7.5	C56	Ovary	52	8.7
C80-C85, C96	Lymphoma	36	6.5	C53	Cervix uteri	47	7.9
C73	Thyroid gland	31	5.6	C54-C55	Uterus	37	6.2
C91 - C95	Leukaemia	27	4.9	C00-C06	Lip, tongue and mouth	32	5.4
C15	Oesophagus	25	4.5	C33-C34	Trachea, bronchus and lung	24	4.0
C70-C72	Brain and central nervous system	24	4.4	C15	Oesophagus	23	3.9
C67	Bladder	22	4.0	C80-C85, C96	Lymphoma	20	3.0
Total		591	107.5	Total		790	132.4

Leading cancer incidence data by sex in Matara District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	91	21.7	C50	Breast	167	36.7
C18-C20	Colon and rectum	56	13.4	C73	Thyroid gland	91	20.0
C33-C34	Trachea, bronchus and lung	53	12.7	C18-C20	Colon and rectum	51	11.2
C61	Prostate	31	7.4	C56	Ovary	36	7.9
C15	Oesophagus	27	6.5	C53	Cervix uteri	31	6.8
C22	Liver and intrahepatic bile duct	26	6.2	C54-C55	Uterus	26	5.7
C09-C014	Pharynx	24	5.7	C15	Oesophagus	21	4.6
C91 - C95	Leukaemia	23	5.5	C80-C85,C96	Lymphoma	20	4.4
C80-C85,C96	Lymphoma	19	4.5	C00-C06	Lip, tongue and mouth	15	3.3
C32	Larynx	18	4.3	C91 - C95	Leukaemia	14	3.1
Total		485	115.9	Total		579	127.2

Leading cancer incidence data by sex in Hambantota District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	96	28.7	C50	Breast	108	31.2
C33-C34	Trachea, bronchus and lung	34	10.2	C73	Thyroid gland	73	21.1
C18-C20	Colon and rectum	32	9.6	C18-C20	Colon and rectum	30	8.7
C61	Prostate	31	9.3	C00-C06	Lip, tongue and mouth	23	6.6
C15	Oesophagus	25	7.5	C53	Cervix uteri	21	6.1
C91- C95	Leukaemia	20	6.0	C56	Ovary	19	5.5
C80-C85, C96	Lymphoma	18	5.4	C54-C55	Uterus	16	4.6
C73	Thyroid gland	12	3.6	C91 - C95	Leukaemia	16	4.6
C32	Larynx	12	3.6	C80-C85,C96	Lymphoma	14	4.0
C67	Bladder	12	3.6	C33-C34	Trachea, bronchus and lung	12	3.5
Total		386	115.4	Total		401	115.8

Northern Province

Leading cancer incidence data by sex in Jaffna District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	83	28.1	C50	Breast	103	30.9
C09-C014	Pharynx	46	15.6	C53	Cervix uteri	33	9.9
C15	Oesophagus	40	13.6	C56	Ovary	31	9.3
C18-C20	Colon and rectum	24	8.1	C15	Oesophagus	30	9.0
C33-C34	Trachea, bronchus and lung	23	7.8	C00-C06	Lip, tongue and mouth	27	8.1
C61	Prostate	22	7.5	C54-C55	Uterus	27	8.1
C32	Larynx	21	7.1	C73	Thyroid gland	25	7.5
C22	Liver and intrahepatic bile duct	11	3.7	C80-C85, C96	Lymphoma	14	4.2
C80-C85, C96	Lymphoma	10	3.4	C18-C20	Colon and rectum	12	3.6
C91 - C95	Leukaemia	8	2.7	C70-C72	Brain and central nervous system	11	3.3
Total		372	126.0	Total		410	123.0

Leading cancer incidence data by sex in Kilinochchi District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	15	30.3	C50	Breast	12	24.2
C09-C014	Pharynx	7	14.1	C00-C06	Lip, tongue and mouth	11	22.2
C18-C20	Colon and rectum	5	10.1	C53	Cervix uteri	9	18.1
C61	Prostate	5	10.1	C15	Oesophagus	8	16.1
C15	Oesophagus	4	8.1	C73	Thyroid gland	6	12.1
C73	Thyroid gland	3	6.1	C56	Ovary	5	10.1
C33-C34	Trachea, bronchus and lung	2	4.0	C54-C55	Uterus	3	6.0
C22	Liver and intrahepatic bile duct	2	4.0	C18-C20	Colon and rectum	2	4.0
C91 - C95	Leukaemia	2	4.0	C33-C34	Trachea, bronchus and lung	2	4.0
C16	Stomach	2	4.0	C16	Stomach	1	2.0
Total		57	115.2	Total		67	134.9

Leading cancer incidence data by sex in Mannar District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	15	22.6	C50	Breast	10	14.6
C33-C34	Trachea, bronchus and lung	5	7.5	C73	Thyroid gland	7	10.2
C18-C20	Colon and rectum	4	6.0	C53	Cervix uteri	6	8.7
C61	Prostate	4	6.0	C15	Oesophagus	6	8.7
C67	Bladder	4	6.0	C56	Ovary	6	8.7
C15	Oesophagus	3	4.5	C18-C20	Colon and rectum	4	5.8
C73	Thyroid gland	3	4.5	C00-C06	Lip, tongue and mouth	3	4.4
C32	Larynx	3	4.5	C54-C55	Uterus	3	4.4
C16	Stomach	2	3.0	C16	Stomach	2	2.9
C08	Unspecified major salivary gland	2	3.0	C67	Bladder	2	2.9
Total		55	82.9	Total		59	85.9

Leading cancer incidence data by sex in Mullaitivu District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	19	19.7	C50	Breast	16	16.1
C15	Oesophagus	5	5.2	C53	Cervix uteri	10	10.1
C33-C34	Trachea, bronchus and lung	3	3.1	C15	Oesophagus	5	5.0
C09-C014	Pharynx	3	3.1	C73	Thyroid gland	3	3.0
C32	Larynx	3	3.1	C80-C85, C96	Lymphoma	3	3.0
C43-C44	Skin	3	3.1	C70-C72	Brain and central nervous system	3	3.0
C64	Kidney	2	2.1	C56	Ovary	2	2.0
C61	Prostate	1	1.0	C00-C06	Lip, tongue and mouth	2	2.0
C18-C20	Colon and rectum	1	1.0	C54-C55	Uterus	1	1.0
C91 - C95	Leukaemia	1	1.0	C16	Stomach	1	1.0
Total		50	51.9	Total		52	52.4

Leading cancer incidence data by sex in Vavuniya District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	17	29.4	C50	Breast	21	36.7
C32	Larynx	9	15.5	C73	Thyroid gland	13	22.7
C61	Prostate	7	12.1	C53	Cervix uteri	11	19.2
C18-C20	Colon and rectum	6	10.4	C15	Oesophagus	11	19.2
C91 - C95	Leukaemia	5	8.6	C00-C06	Lip, tongue and mouth	8	14.0
C33-C34	Trachea, bronchus and lung	4	6.9	C54-C55	Uterus	6	10.5
C15	Oesophagus	4	6.9	C56	Ovary	4	7.0
C09-C014	Pharynx	4	6.9	C33-C34	Trachea, bronchus and lung	4	7.0
C90	Multiple myeloma	4	6.9	C91 - C95	Leukaemia	4	7.0
C70-C72	Brain and central nervous system	3	5.2	C18-C20	Colon and rectum	4	7.0
Total		74	128.7	Total		100	174.6

Eastern Province

Leading cancer incidence data by sex in Ampara District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	52	14.2	C50	Breast	82	21.1
C18-C20	Colon and rectum	31	8.5	C73	Thyroid gland	47	12.1
C15	Oesophagus	26	7.1	C00-C06	Lip, tongue and mouth	27	6.9
C33-C34	Trachea, bronchus and lung	26	7.1	C56	Ovary	24	6.2
C09-C014	Pharynx	21	5.8	C18-C20	Colon and rectum	21	5.4
C61	Prostate	19	5.2	C54-C55	Uterus	13	3.3
C67	Bladder	14	3.8	C91 - C95	Leukaemia	12	3.1
C73	Thyroid gland	11	3.0	C15	Oesophagus	11	2.8
C91 - C95	Leukaemia	11	3.0	C53	Cervix uteri	11	2.8
C80-C85, C96	Lymphoma	9	2.5	C33-C34	Trachea, bronchus and lung	8	2.1
Total		298	81.6	Total		330	84.8

Leading cancer incidence data by sex in Batticaloa District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	37	13.2	C50	Breast	85	27.5
C33-C34	Trachea, bronchus and lung	32	11.4	C73	Thyroid gland	24	7.8
C18-C20	Colon and rectum	25	8.9	C18-C20	Colon and rectum	22	7.1
C15	Oesophagus	22	7.8	C56	Ovary	20	6.5
C67	Bladder	14	5.0	C53	Cervix uteri	19	6.2
C80-C85, C96	Lymphoma	10	3.6	C00-C06	Lip, tongue and mouth	17	5.5
C91 - C95	Leukaemia	10	3.6	C15	Oesophagus	14	4.5
C22	Liver and intrahepatic bile duct	9	3.2	C91 - C95	Leukaemia	11	3.6
C61	Prostate	8	2.9	C33-C34	Trachea, bronchus and lung	10	3.2
C32	Larynx	7	2.5	C54-C55	Uterus	8	2.6
Total		243	86.6	Total		301	97.4

Leading cancer incidence data by sex in Trincomalee District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	28	12.8	C50	Breast	50	22.3
C33-C34	Trachea, bronchus and lung	14	6.4	C00-C06	Lip, tongue and mouth	20	8.9
C67	Bladder	14	6.4	C73	Thyroid gland	18	8.0
C15	Oesophagus	11	5.0	C56	Ovary	16	7.1
C09-C014	Pharynx	10	4.6	C18-C20	Colon and rectum	13	5.8
C73	Thyroid gland	9	4.1	C54-C55	Uterus	13	5.8
C18-C20	Colon and rectum	8	3.6	C15	Oesophagus	7	3.1
C80-C85, C96	Lymphoma	7	3.2	C53	Cervix uteri	6	2.7
C70-C72	Brain and central nervous system	6	2.7	C33-C34	Trachea, bronchus and lung	6	2.7
C61	Prostate	5	2.3	C91 - C95	Leukaemia	4	1.8
Total		146	66.6	Total		196	87.3

North Western Province

Leading cancer incidence data by sex in Kurunegala District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	243	29.0	C50	Breast	406	44.8
C15	Oesophagus	144	17.2	C73	Thyroid gland	179	19.8
C18-C20	Colon and rectum	122	14.6	C18-C20	Colon and rectum	144	15.9
C09-C014	Pharynx	99	11.8	C56	Ovary	109	12.0
C33-C34	Trachea, bronchus and lung	97	11.6	C53	Cervix uteri	102	11.3
C61	Prostate	56	6.7	C54-C55	Uterus	99	10.9
C22	Liver and intrahepatic bile duct	54	6.5	C15	Oesophagus	66	7.3
C73	Thyroid gland	51	6.1	C80-C85,C96	Lymphoma	39	4.3
C50	Breast	41	4.9	C00-C06	Lip, tongue and mouth	34	3.8
C32	Larynx	40	4.8	C70-C72	Brain and central nervous system	33	3.6
Total		1267	151.4	Total		1445	159.5

Leading cancer incidence data by sex in Puttlam District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	101	24.6	C50	Breast	107	24.4
C18-C20	Colon and rectum	31	7.5	C73	Thyroid gland	57	13.0
C15	Oesophagus	30	7.3	C53	Cervix uteri	50	11.4
C09-C014	Pharynx	27	6.6	C56	Ovary	30	6.8
C33-C34	Trachea, bronchus and lung	26	6.3	C54-C55	Uterus	28	6.4
C61	Prostate	21	5.1	C00-C06	Lip, tongue and mouth	23	5.2
C73	Thyroid gland	21	5.1	C18-C20	Colon and rectum	21	4.8
C22	Liver and intrahepatic bile duct	21	5.1	C33-C34	Trachea, bronchus and lung	18	4.1
C91 - C95	Leukaemia	20	4.9	C91 - C95	Leukaemia	18	4.1
C67	Bladder	15	3.6	C15	Oesophagus	12	2.7
Total		428	104.0	Total		457	104.2

North Central Province

Leading cancer incidence data by sex in Anuradhapura District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	98	21.0	C50	Breast	135	27.6
C33-C34	Trachea, bronchus and lung	64	13.7	C73	Thyroid gland	104	21.2
C15	Oesophagus	38	8.1	C53	Cervix uteri	45	9.2
C18-C20	Colon and rectum	37	7.9	C54-C55	Uterus	34	6.9
C09-C014	Pharynx	29	6.2	C56	Ovary	32	6.5
C32	Larynx	28	6.0	C18-C20	Colon and rectum	25	5.1
C61	Prostate	26	5.6	C91 - C95	Leukaemia	22	4.5
C91 - C95	Leukaemia	26	5.6	C80-C85, C96	Lymphoma	20	4.1
C80-C85, C96	Lymphoma	25	5.3	C00-C06	Lip, tongue and mouth	15	3.1
C73	Thyroid gland	23	4.9	C15	Oesophagus	12	2.4
Total		529	113.2	Total		538	109.5

Leading cancer incidence data by sex in Polonnaruwa District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	36	16.2	C50	Breast	75	33.0
C33-C34	Trachea, bronchus and lung	32	14.4	C73	Thyroid gland	69	30.4
C09-C014	Pharynx	20	9.0	C53	Cervix uteri	22	9.7
C18-C20	Colon and rectum	17	7.7	C18-C20	Colon and rectum	20	8.8
C61	Prostate	17	7.7	C15	Oesophagus	18	7.9
C15	Oesophagus	13	5.9	C54-C55	Uterus	16	7.0
C40-C41	Bone	9	4.1	C56	Ovary	15	6.6
C91 - C95	Leukaemia	8	3.6	C91 - C95	Leukaemia	12	5.3
C73	Thyroid gland	8	3.6	C00-C06	Lip, tongue and mouth	10	4.4
C67	Bladder	8	3.6	C70-C72	Brain and central nervous system	9	4.0
Total		230	103.5	Total		330	145.3

Uva Province

Leading cancer incidence data by sex in Badulla District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	118	27.3	C50	Breast	146	31.3
C33-C34	Trachea, bronchus and lung	44	10.2	C73	Thyroid gland	68	14.6
C18-C20	Colon and rectum	37	8.6	C00-C06	Lip, tongue and mouth	44	9.4
C15	Oesophagus	28	6.5	C56	Ovary	42	9.0
C67	Bladder	22	5.1	C15	Oesophagus	39	8.4
C80-C85,C96	Lymphoma	21	4.9	C54-C55	Uterus	36	7.7
C32	Larynx	20	4.6	C53	Cervix uteri	35	7.5
C61	Prostate	17	3.9	C18-C20	Colon and rectum	35	7.5
C91 - C95	Leukaemia	17	3.9	C33-C34	Trachea, bronchus and lung	12	2.6
C09-C014	Pharynx	14	3.2	C91 - C95	Leukaemia	10	2.1
Total		456	105.5	Total		561	120.1

Leading cancer incidence data by sex in Monaragala District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	58	23.0	C50	Breast	59	23.1
C33-C34	Trachea, bronchus and lung	39	15.4	C73	Thyroid gland	52	20.3
C61	Prostate	25	9.9	C53	Cervix uteri	28	10.9
C18-C20	Colon and rectum	21	8.3	C00-C06	Lip, tongue and mouth	16	6.3
C15	Oesophagus	14	5.5	C56	Ovary	16	6.3
C91 - C95	Leukaemia	10	4.0	C18-C20	Colon and rectum	16	6.3
C80-C85, C96	Lymphoma	10	4.0	C15	Oesophagus	13	5.1
C73	Thyroid gland	10	4.0	C33-C34	Trachea, bronchus and lung	12	4.7
C09-C014	Pharynx	8	3.2	C70-C72 Brain and central nervous system		8	3.1
C70-C72	Brain and central nervous system	7	2.8	C80-C85, C96	Lymphoma	6	2.3
Total		261	103.3	Total		263	102.8

Sabaragamuwa Province


Leading cancer incidence data by sex in Rathnapura District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	233	39.6	C50	Breast	224	37.0
C18-C20	Colon and rectum	67	11.4	C73	Thyroid gland	126	20.8
C61	Prostate	52	8.8	C00-C06	Lip, tongue and mouth	64	10.6
C15	Oesophagus	45	7.7	C53	Cervix uteri	58	9.6
C09-C014	Pharynx	43	7.3	C15	Oesophagus	54	8.9
C73	Thyroid gland	38	6.5	C18-C20	Colon and rectum	50	8.3
C33-C34	Trachea, bronchus and lung	32	5.4	C54-C55	Uterus	46	7.6
C80-C85, C96	Lymphoma	29	4.9	C56	Ovary	40	6.6
C32	Larynx	25	4.3	C33-C34	Trachea, bronchus and lung	28	4.6
C91 - C95	Leukaemia	19	3.2	C91 - C95	Leukaemia	26	4.3
Total		744	126.5	Total		865	143.1


Leading cancer incidence data by sex in Kegalle District, 2022

Male				Female			
Site (ICD 10 Code)		Cases	CR	Site (ICD 10 Code)		Cases	CR
C00-C06	Lip, tongue and mouth	104	24.3	C50	Breast	173	36.8
C15	Oesophagus	63	14.7	C73	Thyroid gland	90	19.1
C18-C20	Colon and rectum	56	13.1	C18-C20	Colon and rectum	60	12.8
C09-C014	Pharynx	44	10.3	C53	Cervix uteri	50	10.6
C33-C34	Trachea, bronchus and lung	40	9.3	C56	Ovary	47	10.0
C61	Prostate	35	8.2	C54-C55	Uterus	39	8.3
C32	Larynx	24	5.6	C00-C06	Lip, tongue and mouth	26	5.5
C80-C85, C96	Lymphoma	18	4.2	C15	Oesophagus	25	5.3
C22	Liver and intrahepatic bile duct	15	3.5	C91 - C95	Leukaemia	17	3.6
C91 - C95	Leukaemia	14	3.3	C33-C34	Trachea, bronchus and lung	11	2.3
Total		534	124.6	Total		653	138.9


Figure 60: Cancer incidence data by districts among males in Sri Lanka, 2022




Total Cases	District available	%	District missing	%
3013	2300	76	713	24




Total Cases	District available	%	District missing	%
1564	1128	72	436	28




Total	District available	%	District missing	%
1381	1047	76	334	24




Total	District available	%	District missing	%
1226	885	72	341	28




Total	District available	%	District missing	%
1178	849	72	329	28




Total	District available	%	District missing	%
877	675	77	202	23




Total	District available	%	District missing	%
601	474	79	127	21



Total	District available	%	District missing	%
600	415	69	185	31





Total	District available	%	District missing	%
560	454	81	106	19




Total	District available	%	District missing	%
573	343	60	230	40

Figure 61: Cancer incidence data by districts among females in Sri Lanka, 2022




Colon and rectum (Female)




Total	District available	%	District missing	%
1519	1084	71	435	29


Uterus (Female)



Total	District available	%	District missing	%
1238	876	71	362	29




Total	District available	%	District missing	%
1226	972	79	254	21




Total	District available	%	District missing	%
1112	925	83	187	17

Oesophagus (Female)




Total	District available	%	District missing	%
805	591	73	214	27


Lip, tongue and mouth (Female)



Total	District available	%	District missing	%
792	626	79	166	21



Total	District available	%	District missing	%
553	395	71	158	29



Total	District available	%	District missing	%
428	326	76	102	24

Cancer Mortality Data Sri Lanka - 2022

Introduction

Mortality data due to cancers were obtained through the (i) Department of Census & Statistics website based on data derived from the vital registration system of Sri Lanka, (ii) Annual Health Bulletin of Ministry of Health based on Indoor morbidity mortality return (IMMR) received from government hospital network.

(i) Mortality data through the Vital Registration System

Information on deaths occurred due to cancers throughout the country are obtained through the cause of death data reported to vital registration system of Sri Lanka. This information is published by the Department of Census and Statistics. Cause of death data of year 2020 is the latest available information. (http://www.statistics.gov.lk/Population/Vital_Statistics-2020)

Table 36: Deaths due to neoplasm out of all deaths reported to Vital Registration System of Sri Lanka, 2001-2022

Year	Population	Cancer Deaths		
		No.	CDR	PMR (%)
2001	18,797,000	8,063	42.9	7.1
2002	18,921,000	7,986	42.2	7.1
2003	19,173,000	8,396	43.8	7.3
2004	19,435,000	9,127	47.0	7.9
2005	19,644,000	9,403	47.9	7.1
2006	19,958,000	10,386	52.3	8.8
2007	20,039,000	10,631	53.1	8.9
2008*	20,246,000			
2009	20,450,000	11,286	55.2	8.8
2010	20,653,000	11,836	57.3	9.1
2011	20,892,000	12,267	58.7	10.0
2012	20,359,439	12,581	61.8	10.2
2013	20,585,041	12,954	62.9	10.2
2014	20,777,595	13,514	65.0	10.5
2015	20,970,488	13,825	65.9	10.5
2016*	21,202,665			
2017*	21,444,350			
2018*	21,669,511			
2019	21,802,903	15,598	71.5	10.7
2020	21,919,415	15,242	69.5	
2021*	22,155,748			
2022*				

Source: Department of Census & Statistics, Sri Lanka

* Not published

CDR-Crude Death Rate due to cancers per 100,000 population

PMR – Proportionate Mortality Ratio out of total deaths

Table 37: Deaths due to neoplasms by sex out of all deaths reported to Vital Registration System of Sri Lanka, 2001-2020

Year		Male			Female		
		No.	CDR	ASDR	No.	CR	ASDR
2001		4375	46.7	52.1	3688	39.1	39.9
2002		4350	46.5	51.2	3636	37.9	38.6
2003		4614	48.7	53.6	3782	38.9	39.6
2004		4942	57.1	57.3	4185	42.9	44.0
2005		4983	50.9	57.0	4420	44.8	45.8
2006		5644	57.1	63.6	4742	47.6	48.7
2007		5827	58.5	65.4	4804	47.6	48.8
2008*							
2009		6105	60.2	67.6	5181	50.3	52.0
2010		6438	62.8	70.9	5398	51.9	53.5
2011		6641	64.0	72.5	5626	53.5	55.3
2012		6908	70.1	65.5	5673	54.0	44.4
2013		7166	71.9	67.4	5788	54.5	44.9
2014		7459	74.2	69.5	6055	56.5	46.5
2015		7726	76.1	71.4	6099	56.4	46.4
2016*							
2017*							
2018*							
2019		8669	82.1	71.5	6929	61.6	50.6
2020		8545	80.5	76.3	6697	59.2	48.7

Source: Department of Census & Statistics, Sri Lanka

* Not published

CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population




Figure 62: Crude Death Rates due to cancers in Sri Lanka based on Vital Registration System, 2001-2020




Figure 63: Age Standardized Death Rates due to cancer based on Vital Registration System, 2001-2020

Table 38: Number of deaths and Crude Death Rates due to cancer by sex and site of cancer based on deaths reported to Vital Registration System of Sri Lanka, 2020

ICD- 10 Code	Site of Cancer	Male		Female		Total	
		No.	CDR	No.	CDR	No.	CDR
C00-C14	Lip, oral cavity and pharynx	885	8.3	243	2.1	1128	5.1
C15	Oesophagus	421	4.0	255	2.3	676	3.1
C16	Stomach	211	2.0	171	1.5	382	1.7
C18-C21	Colon, rectum and anus	265	2.5	251	2.2	516	2.4
C22	Liver and intrahepatic bile ducts	704	6.6	293	2.6	997	4.5
C25	Pancreas	110	1.0	78	0.7	188	0.9
C32	Larynx	155	1.5	35	0.3	190	0.9
C33-C34	Trachea, bronchus and lung	1,031	9.7	396	3.5	1427	6.5
C43	Melanoma of skin	9	0.1	3	0.0	12	0.1
C50	Breast	19	0.2	773	6.8	792	3.6
C53	Cervix uteri	-		189	1.7	189	1.7
C54-C55	Uterus	-		293	2.6	293	2.6
C56	Ovary	-		275	2.4	275	2.4
C61	Prostate	252	2.4	-		252	2.4
C67	Bladder	161	1.5	28	0.2	189	0.9
C70-C72	Meninges, brain and other parts of central nervous system	275	2.6	232	2.1	507	2.3
C82-C85	Non-Hodgkin s lymphoma	143	1.3	90	0.8	233	1.1
C90	Multiple myeloma and malignant plasma cell neoplasms	96	0.9	81	0.7	177	0.8
C91-C95	Leukemia	323	3.0	304	2.7	627	2.9
Other C00 - C95	Remainder of malignant neoplasm	3,385	31.9	2,619	23.2	6004	27.4
D00-D48	Remainder of neoplasms D00-D48	103	1.0	88	0.8	191	0.9
COO-D48	All Neoplasms	8548	56.1	6697	43.9	15245	69.6

*No. – Number of deaths, ** CDR – Crude Death Rate




Figure 64: Proportion of leading cancer deaths among males based on deaths reported to Vital Registration System of Sri Lanka, 2020




Figure 65: Proportion of leading cancer deaths among females based on deaths reported to Vital Registration System of Sri Lanka, 2020




Figure 66: Age Standardized Mortality Rates due to cancer of Trachea, bronchus and lung




Figure 67: Age Standardized Mortality Rates due to cancer of Lip, oral cavity and pharynx




Figure 68: Age Standardized Mortality Rates due to cancer of Breast




Figure 69: Age Standardized Mortality Rates due to cancer of Liver and intrahepatic bile ducts




Figure 70: Age Standardized Mortality Rates due to cancer of Oesophagus




Figure 71: Age Standardized Mortality Rates due to cancer of Cervix uteri




Figure 72: Age Standardized Mortality Rates due to cancer of Colon, rectum and anus




Figure 73: Age Standardized Mortality Rates due to cancer of Prostate

(ii) Mortality data through Indoor Morbidity Mortality Return

Mortality data due to cancers were obtained through Annual Health Bulletin of Ministry of Health based on Indoor Morbidity Mortality Return (IMMR).

Table 39: Deaths due to cancer among males and females in hospitals in Sri Lanka, 2005-2022

Year	No. of hospital deaths due to cancer		Total
	Male	Female	
2005			2753
2006			3241
2007			3498
2008			3485
2009			3774
2010			4449
2011			4631
2012	2538	1931	4519
2013	2559	1980	4539
2014	2867	2128	4995
2015	2657	2141	4798
2016	2878	2270	5148
2017	2720	2218	4938
2018	3223	2566	5789
2019	3462	2834	6296
2020	2947	2406	5353
2021	2779	2333	5112
2022	3074	2660	5734

Sources: Annual Health Bulletin 2005 to 2022

Table 40: Deaths due to cancer in hospitals, crude hospital annual death rates due to cancer and proportionate mortality ratio for cancer out of all hospital deaths in Sri Lanka, 2005-2022

Year	No. of hospital deaths due to cancer	Crude hospital annual death rate due to cancers per 100,000 population	Proportionate Mortality Ratio (PMR) out of all hospital deaths
2005	2753	14.0	8.3
2006	3241	16.3	9.9
2007	3498	17.5	10.1
2008	3485	17.2	9.8
2009	3774	18.5	10.0
2010	4449	21.5	11.1
2011	4631	22.2	11.8
2012	4519	22.2	11.6
2013	4539	22.2	11.2
2014	4995	24.0	11.7
2015	4798	22.9	11.0
2016	5148	24.3	12.0
2017	4938	23.0	10.5
2018	5789	26.7	11.7
2019	6296	28.9	11.7
2020	5353	24.4	11.2
2021	5112	23.1	8.0
2022	5734	25.9	8.6

Sources: Annual Health Bulletin 2005 to 2022

Table 41: Hospitalizations, hospital deaths and case fatality rate due to cancer in year 2022 by RDHS divisions in Sri Lanka

*RDHS Area	Hospital Admissions due to cancer			**Case fatality rate
	Total hospital admissions	Live hospital discharges	No. hospital deaths	
Colombo	61,298	59,122	2,176	3.5
Gampaha	5,651	5,307	344	6.1
Kalutara	2,655	2,574	81	3.1
Kandy	20,364	19,812	552	2.7
Matale	1,799	1,714	85	4.7
Nuwara Eliya	1,624	1,567	57	3.5
Galle	15,528	15,072	456	2.9
Matara	3,845	3,756	89	2.3
Hambanthota	2,361	2,306	55	2.3
Jaffna	5,507	5,372	135	2.5
Kilinochchi	261	254	7	2.7
Mullaitivu	172	169	3	1.7
Vavuniya	392	375	17	4.3
Mannar	295	286	9	3.1
Batticaloa	3,444	3,393	51	1.5
Ampara	375	328	47	12.5
Kalmunai	800	778	22	2.8
Trincomalee	629	611	18	2.9
Kurunegala	7,886	7,473	413	5.2
Puttalam	715	645	70	9.8
Anuradhapura	6,688	6,388	300	4.5
Polonnaruwa	1,145	1,004	141	12.3
Badulla	5,832	5,573	259	4.4
Monaragala	960	906	54	5.6
Ratnapura	5,114	4,917	197	3.9
Kegalle	1,118	1,022	96	8.6
Sri Lanka	156,458	150,724	5,734	3.67

*RDHS area – Regional Director of health Services divisions

**Case Fatality rate = $\frac{\text{No. of hospital deaths due to cancers}}{\text{Total number of hospital admissions due to cancers}} \times 100$

Statistical Terminology

Population at risk

The population at risk includes all individuals susceptible to a specific cancer. It is defined on the basis of demographic variables, such as place of residence, sex, age group. Years of risk duration are counted in person-years.

Incidence

Incidence quantifies the number of new cases that develop in a population of individuals at risk during a specified time interval. Usually, it is given as per 100,000 population per year.

Mortality

Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.

$$\text{Crude incidence rate} = \frac{\text{Total number of cases in the year}}{\text{Total midyear population at risk}} \times 100,000$$

$$\text{Crude death rate} = \frac{\text{Total number of deaths in the year}}{\text{Total midyear population at risk}} \times 100,000$$

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five- year age categories are used

$$\text{Age-specific incidence rate} = \frac{\text{Number of cases in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

$$\text{Age-specific death rate} = \frac{\text{Number of deaths in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

ASR (Age standardized rate)

An age-standardized rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the *standard population*. The most frequently used standard population is the *World Standard Population*. The calculated mortality rate is then called age-standardized mortality rate (world). The world standard population used within the application is as proposed by Segi (1960) and modified by Doll and *al.* (1966). The ASR is also expressed per 100,000.

Age distribution of the world standard population	
Age group	w _i
0-4	12000
5-9	10000
10-14	9000
15-19	9000
20-24	8000
25-29	8000
30-34	6000
35-39	6000
40-44	6000
45-49	6000
50-54	5000
55-59	4000
60-64	4000
65-69	3000
70-74	2000
75-79	1000
80-84	500
85+	500
Total	100000

Life time risk (Cumulative Risk)

Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease within a specified age interval within a time period.

(The cumulative risk is the risk which an individual would have of developing the cancer under study during a certain age span if no other causes of death were in operation)

List of References

Department of Census and Statistics <http://www.statistics.gov.lk/Population/StaticalInformation/VitalStatistics> [16 May 2025]

Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D.M., Whelan S. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva

Glossary of statistical terms; <http://www-dep.iarc.fr/WHOdb/glossary.htm> [21 August 2025]

ICD 10-10th revision, Fifth edition 2016, World Health Organization

International Association of Cancer Registries, http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=68&Itemid=445 [10 July 2025]

International Classification of Childhood Cancer, Third Edition, *Cancer 2005; 103: 1457-67*

Ministry of Health, <https://www.health.gov.lk/annual-health-bulletin/> [24 July 2025]



National Cancer Control Programme
Ministry of Health
555/5, Public Health Complex
Elvitigala Mawatha, Narahenpita, Colombo 5
Sri Lanka
+94112368627
www.nccp.health.gov.lk

ISBN 978 624 6511 50 0

